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ABSTRACT
Behavioral responses to stressors can be influenced in different ways by both serotonin (5-HT)
agonists and antagonists. Further study, of both different stressors as well as different 5-HT
agents, is needed to clarify the place of 5-HT in stress responding. To date, no published report
has investigated the influence of centrally and/or peripherally administered 5-HT 2A/C agonist
B

B

DOI or the 5-HT 2A/C antagonist ketanserin on behaviors evoked by tail pinch or open field
B

B

stressors. Five separate, related experiments were conducted to investigate this influence. It was
hypothesized that that peripherally (Experiment 1), centrally (Experiment 2), and centrally +
peripherally (Experiment 3) injected DOI would reduce stress responding to tail pinch and open
field stressors, and that peripheral injection of ketanserin (Experiment 4) would increase
behavioral responding to stress when injected alone, as well as reverse the reduction in
behavioral responding from injection of DOI (Experiment 5). The results strongly supported the
hypotheses. Administration of DOI resulted in significantly decreased behavioral responding to
tail pinch stress in all five experiments, regardless of route of administration. Concomitant
peripheral administration of KET and DOI resulted in a reversal of the decrease in stress-evoked
behaviors seen with administration of DOI alone. This is the first report of the influence of
centrally and peripherally administered DOI on behaviors evoked by tail pinch or open field
stress, and the reversal of that influence by the 5-HT 2A/C antagonist ketanserin. Future
B

B

investigations should be designed to study whether the effects observed in the current report are
centrally or peripherally mediated.

x

INTRODUCTION
Serotonin
Serotonin is a substance present in both animals and plants, the properties of which have
been observed and researched for over 100 years. Sixty years before it was isolated and identified,
the vasoconstricting properties of serotonin in mammals were observed. By the 1930s and 40s,
serotonin had been identified in blood serum in the United States and (called enteramine) in the
gut of vertebrate animals in Europe, though it was not until the early 1950s that these two were
recognized as identical substances (Villalon, Terron, Ramirez-San Juan, & Saxena, 1995).
Serotonin has since been identified as a transmitter substance, known to be present in the
periphery and the central nervous system.
The neurotransmitter 3-(β-aminoethyl)-5-hydroxyindole, commonly known today as 5hydroxytryptamine, or serotonin (5-HT), has become the most thoroughly studied of the biogenic
amines due to its established influence on several physiological and psychological phenomena
(Graeff, 1994) (Figure 1). 5-HT is derived from the amino acid L-tryptophan, which is taken into
cells and converted into 5-hydroxytryptophan by the enzyme tryptophan-5-hydroxylase. Another
enzyme, α-aromatic amino acid decarboxylase, converts the 5-hydroxytryptophan into 5hydroxytryptamine. After 5-HT is released from the cell into the synapse, reuptake of the
transmitter (active transport from the synaptic cleft back into the cell) occurs. Once returned to
the interior of the cell, 5-HT is broken down by monoamine oxidase A, forming 5hydroxyindoleacetaldehyde. This metabolite is in turn made into 5-hydroxyindoleacetic acid (5HIAA) by the enzyme aldehyde dehydrogenase (Watling, 2001).
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Figure1: 5-HT chemical structure.
From http://www.biopsychiatry.com/serotonin/

5-HT can be found in three cell types in the mammalian body: neurons in the CNS, blood
platelets, and enterochromaffin cells of the GI tract (Steckler, Ruggeberg-Schmidt, & MullerOerlinghausen, 1993). Whereas the cells in the GI tract and the neurons in the CNS are able to
synthesize 5-HT from the precursor L-tryptophan and application of the enzymatic cascade
outlined above, platelets must rely on uptake of the transmitter from the blood (Lingjaerde, 1969).
The 5-HT in platelets is stored as a 5-HT/ATP complex, which is released during vascular
damage, helping to reduce blood loss by exerting vasoconstrictive properties on the surrounding
vessels (Martin, 1994). Stimulation of the vagal nerve releases 5-HT from the enterochromaffin
cells in the gut causing nausea and vomiting via stimulation of the area postrema (Minami et al.,
2003). Release of 5-HT from neurons in the CNS can result in many potential physiological and
behavioral changes, depending upon the receptor subtypes involved.
Review of 5-HT Receptor Function
The primordial 5-HT receptor is, based on molecular evolution analysis, reportedly seven
to eight hundred million years old, and may have been the first evolutionary change in receptor
structure from the g-protein receptors known to be present in yeasts and molds one billion years
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ago. In fact, some theorize that all the biogenic amine receptors are mutants (i.e., descendants) of
the original 5-HT receptor (Peroutka, 1994). The current classification and understanding of the
5-HT receptor system is based on discoveries in the middle of the last century.
While others had suggested that the action of 5-HT in vasoconstriction and smooth muscle
contraction in the gut could be due to the presence of different receptors (Villalon et al., 1995),
Zuleika Picarelli and Sir John Gaddum were the first to recognize and classify two distinct 5-HT
receptors in guinea pig intestine, which they called ‘M’ and ‘D’ after the two substances
(morphine and dibenzyline) that prevented the contraction of this smooth muscle (Gaddum &
Picarelli, 1957). Ten years following this discovery and original classification system, the ‘M’ and
‘D’ receptor distinction was thought to be insufficient in that it did not account for the failure of
some potent 5-HT ‘D’ antagonists to prevent the vasoconstrictive properties of 5-HT in the
canine carotid while successfully blocking vasoconstriction at other vascular sites. These failures
led researchers to believe that more than two 5-HT receptors existed in the mammalian
circulatory system (Villalon et al., 1995). During the 1970’s technological advances in radioligand
labeling of 5-HT agonists and antagonists allowed researchers to begin classifying receptor
subtypes with more precision, and by the mid-1980’s the need for a new classification system was
apparent (Villalon et al., 1995).
Today there are at least seven 5-HT receptor families known to be present in human
and/or animal tissue. Within three of the seven receptor families, there exist several receptor
subtypes. For example, in the 5-HT2 receptor family there are three subtypes, designated 5-HT2A,
2B, 2C

. With the advent of more advanced ligand binding techniques, improved molecular genetic

studies of the 5-HT receptors, and insight into the second messenger systems involved in
postsynaptic receptor activation, the identification of new receptor subtypes has increased
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dramatically in the recent past – bringing the total number of known 5-HT receptors to 14
(Barnes & Sharp, 1999). This large number of receptors is thought to be a function of the 5-HT
system’s evolutionary age (Peroutka, 1994). The function and activity of several of these
receptors has not yet been discovered. The distribution, location, and function of the 5-HT1, 5HT2, and 5-HT3 families are the most well-profiled of the receptor families.
The 5-HT1A receptor is located both pre- and postsynaptically (Barnes et al., 1999). This
autoreceptor controls reuptake of serotonin after it is released into the synaptic cleft. The
presynaptic receptors are located primarily in the dorsal raphe nucleus (DRN). The postsynaptic
5-HT1A receptors are located predominately in the hippocampus, but are also located in the
septum, neocortex, hypothalamus, and parts of the amygdala (Graeff, 1993). Both the pre- and
postsynaptic 5-HT1A receptors work through the cyclic adenosine monophosphate (cAMP)
second messenger system, decreasing cAMP activity when stimulated (Humphrey, Hartig, &
Hoyer, 1993). Despite the fact that the pre- and postsynaptic receptors use the same second
messenger system and are not morphologically distinct, 5-HT1A agonists and antagonists do not
act the same at both receptors. For example, the 5-HT1A agonist ipsapirone is a full agonist of the
presynaptic autoreceptors in the DRN, but is an incomplete agonist at the postsynaptic receptor
located outside of the DRN (Graeff, Viana, & Mora, 1997). Also, the pre- and postsynaptic 5HT1A receptors show different patterns of reactivity with repeated exposure to agonists or
selective serotonin reuptake inhibitors (SSRIs). While the presynaptic receptor tends to show
desensitization with chronic administration of these agents, the postsynaptic receptor does not
(Blier, de Montigny, & Chaput, 1987).
When stimulated, the 5-HT1B receptors (prevalent in rodents) and the 5-HT1D receptors
(prevalent in human tissue) cause a decrease in 5-HT release (Saxena, 1995). The 5-HT1B/D
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receptors are found centrally in the substantia nigra, hippocampus, hypothalamus, and basal
ganglia as well as in the cerebral arteries (Curzon, 1990; Simansky, 1996; Saxena, 1995). Like
the 5-HT1A receptor, the 5-HT1B/D are found both pre- and postsynaptically. They are also
considered autoreceptors and use the same second messenger (cAMP) as the 5-HT1A receptor.
However, the 5-HT1B/D receptors are located on the neuron terminal, unlike the 5-HT1A
autoreceptor, which is located on the neuron soma (Graeff, 1993).
Despite the fact that the 5-HT1D receptor in humans performs the same function in the
circulatory system as the 5-HT1B receptor in rats (e.g., arterial contraction), these two receptors
do not share pharmacological properties, having different agonists and antagonists (Saxena,
1995). The 5-HT1B receptor has also been reported to play a role in ingestive behavior in animals
(Vickers & Dourish, 2004), whereby stimulation of this receptor has been reported to lead to
satiety and decreased food intake (Lee, Kennett, Dourish, & Clifton, 2002; Curzon, 1990) and has
been discussed as a possible mechanism of eating disorders such as anorexia nervosa (Curzon,
1990). However, results of feeding experiments involving the 5-HT1B receptor are ambiguous
(e.g., Grignaschi, Mantelli, & Samanin, 1993; Grignaschi, Sironi, & Samanin, 1996; Grignaschi,
Fanelli, Scagnol, & Samanin, 1999; Hewitt, Lee, Dourish, & Clifton, 2002) and some propose it is
the activity of the 5-HT2C and 1B receptors together that have the strongest influence on feeding
(Schreiber & De Vry, 2002).
The 5-HT1E and 5-HT1F receptors are not well researched, having no known specific
antagonists (Barnes et al., 1999; Watling, 2001). They are known to be present in human tissue
and are thought to use the cAMP second messenger system as do the other members of the 5-HT1
family (Humphrey et al., 1993). When specific antagonists are identified for these receptors,
researchers will be better able to elucidate their function.
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The 5-HT2C receptor was originally classified as 5-HT1C (Pazos, Cortes, & Palacios,
1985). However, molecular cloning research and investigation into the second messenger system
of the 5-HT1C receptor have shown it to be more similar in structure, function, and
pharmacological properties to the 5-HT2 receptor family, and it has therefore been reclassified.
The 5-HT2C receptor is present exclusively postsynaptically and is located in many areas of the
cortex, limbic system, and basal ganglia (Barnes et al., 1999). When activated, 5-HT2C receptors
increase the activity of the postsynaptic neuron via the inositol phosphate second messenger
system (Graeff, 1993). The 5-HT2C receptor is involved in a number of physiologic responses,
including eating, movement, and temperature control (Koek, Jackson, & Colpaert, 1992).
The 5-HT2A receptor was first found in the periphery on smooth muscle cells (Gaddum &
Piccarelli, 1957), however today we know it to be present in the CNS as well. In the brain, the
location of the 5-HT2A receptor overlaps somewhat with the 5-HT2C receptor, with both being
present in the neocortex and limbic system. The 5-HT2A receptor is also highly concentrated in
the amygdala, the claustrum, the olfactory tubercle and the cingulate cortex (Pazos, Probst, &
Palacios, 1987). Like the 5-HT2C receptor, 5-HT2A uses the inosital phosphate second messenger
system to increase the firing rate of the postsynaptic neuron (Boess & Martin, 1994).
The 5-HT2B receptor has been found in both human and rodent tissue (Hoyer et al., 1994).
While it is known to be present in the human brain (Kursar, Nelson, Wainscott, & Baez, 1994)
and involved in the regulation of processes like embryonic cardiac development and hypertension
(Nebigil et al., 2001), this receptor has just recently been located in nervous tissue in the rat
(Nicholson, Small, Dixon, Spanswick, & Lee, 2003). Probably for this reason, this receptor is not
well covered in reviews of 5-HT receptor function, despite the fact that specific agonists and
antagonists and the second messenger system (inosital phosphate) are known.

6

An important and perplexing finding about the 5-HT2 receptor family is that receptors
down-regulate as a result of chronic administration of antagonists. In most receptor systems, and
indeed in the other serotonin receptor families, chronic administration of a pharmacological
antagonist results in receptor up-regulation (i.e., a homeostatic mechanism where decreased
transmitter activity leads to an increase in the number of receptors in the cell membrane). In the
5-HT2 family however, specifically with the 5-HT2A&2C receptors, the opposite effect has been
shown to occur – that is, repeated administration of receptor antagonists, like ketanserin, have
been shown to cause receptor down-regulation (Graeff, 1997). This may be due to these
antagonists having inverse agonist-like properties, whereby the activity of a cell’s second
messenger system is decreased (as would be predicted with the application of an antagonist), but
receptor down-regulation still occurs with chronic application of the antagonist (a phenomenon
that typically occurs with the repeated application of an agonist, not an antagonist) (e.g.,
Labrecque, Fargin, Bouvier, Chidiac, & Dennis, 1995).
The 5-HT3 receptor was also first discovered in the periphery, being the main 5-HT
receptor present in the gut (Watling, 2001). It has been located in areas of the brainstem as well
as the hippocampus, amygdala, nucleus accumbens, entorhinal cortex, and olfactory tubercle
(Graeff, 1993). This is the only known 5-HT receptor where activation directly opens cation
channels without the use of a second messenger system (Derkach, Surprenant, & North, 1989).
The pharmacology and function of the remaining classes of serotonin receptors (5-HT4, 5, 6,
&7

) are poorly characterized at present. The gene that transcribes the 5-HT4 receptor has not yet

been located, but researchers do know that it uses the cAMP second messenger system in the
opposite way that the 5-HT1 family uses it – i.e., activation of 5-HT4 leads to increased cAMP
activity and increased neuronal activity (Chaput, Araneda, & Andrade, 1990). The 5-HT5 family
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(consisting of 5-HT5A and 5-HT5B) is the only class of the seven known receptor types for which
the method of signal transduction (directly through ion channels or a second messenger system) is
unknown (Watling, 2001). As with the 5-HT4 receptor, the genes responsible for transcribing the
5-HT6 & 7 receptors are unknown. It is known that the 5-HT6 & 7 receptors both use the cAMP
system for signal transduction, increasing cAMP activity when stimulated (Barnes et al., 1999).
Influence of 5-HT in the Periphery
5-HT does have several other physiologic actions in the body outside of the CNS, via the
aforementioned gut and platelet stores of the transmitter. 5-HT can impact the respiratory system
by increasing respiration volume and causing bronchial constriction (Saxena & Villalon, 1990).
Systemic administration of 5-HT can cause vasoconstriction or dilation in uninjured vascular
tissue. 5-HT also influences cardiac output and blood pressure by increasing the force of the
contraction of the heart muscle (Gershon, 1991). Stimulation of the smooth muscle of the lower
intestine occurs with 5-HT, but the opposite effect occurs in the large intestine, where 5-HT
inhibits its activity (Dhasmana, Zhu, Cruz, & Villalon, 1993).
5-HT Pathways in the CNS
Several neural pathways originating in the brainstem release 5-HT. The 5-HT neurons in
the pons and medulla send their projections to the spinal cord, where they are involved in the
mediation of nociception and movement (Graeff, 1997). A large population of 5-HT neurons in
the brain is located in the dorsal and median nuclei of the raphe in the brainstem. These nuclei
have diffuse projections to the rest of the brain. The DRN has three primary 5-HT projections
that innervate several brain structures. The first is called the dorsal raphe-cortical tract and
projects from the DRN to the cortex and basal ganglia. A second projection from the DRN, the
dorsal raphe-periventricular tract, innervates the thalamus, the periaqueductal gray, and the
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periventricular nucleus of the hypothalamus. The third major projection from the DRN (and most
diffuse of the three), the dorsal raphe-forebrain tract, goes to the basal ganglia, the thalamus, the
septum, the hippocampus, and the amygdala. Like the DRN, the median raphe nucleus (MRN)
projects (via the median raphe-forebrain tract) to the thalamus, septum, and hippocampus, but
also sends 5-HT fibers to the olfactory bulb (Deakin, 1991; Graeff, 1997). Together, the median
raphe-forebrain tract and the dorsal raphe-forebrain tract make up part of what is known as the
medial forebrain bundle. It is through the projections from the DRN and MRN that 5-HT exerts
its influence on thinking, emotion, and functioning of the neuroendocrine system (Graeff, 1997).
The neurons of the DRN and MRN appear to be morphologically as well as functionally
distinct. Neurons originating in the DRN are small in diameter with little bulging along the axon,
while MRN fibers are thicker and have more large bulges along the axons. Functionally, even
within structures that both the MRN and DRN project to, such as the thalamus and hippocampus,
the DRN fibers synapse with cells that have 5-HT2A and 5-HT2C receptors, and the MRN fibers
synapse with cells that contain 5-HT1A receptors in their membranes (Deakin, 1991). Despite
these distinctions between the MRN and the DRN, the two nuclei are linked directly and indirectly
(via numerous other brain areas).
Role of 5-HT in Psychological Pathologies
5-HT has been implicated in several psychological disorders, such as impulsivity,
psychosis, and depression. Research in this area is extremely profuse and wide-ranging in both
laboratory and clinical settings. While a complete review of this literature is beyond the scope of
this dissertation, a few examples are noted below, followed by a more comprehensive review of 5HT involvement in stress responding, the focus of this research.
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Increased impulsive behavior, including aggression, overeating, alcoholism, as well as
compulsive gambling and sexual activity have been linked to decreased levels of the 5-HT
metabolite, 5-HIAA (Graeff, 1997) and decreased 5-HT uptake sites on platelets (Patkar et al.,
2003). Several atypical antipsychotics prescribed today (e.g., quetiapine fumarate (brand name
Seroquel) and aripiprazole (brand name Abilify)) have a higher affinity for serotonin receptors
than dopamine receptors than do typical antipsychotics and act as 5-HT antagonists (Goldstein,
1999). Many researchers and clinicians now believe that depression is caused, at least in part, by a
net decrease in 5-HT activity in the brain. However, there is disagreement in the field about the
receptor subtypes involved - some feel it is an over-activity of the 5-HT1A autoreceptor (Deakin,
1991), while others (Mikuni, Kagaya, Takahashi, & Meltzer, 1992) believe it is the result of
supersensitivity of the 5-HT2 receptor.
Stress
Stress has been defined in a number of ways, but most definitions include a core
understanding that stress is a physiological and behavioral response to a noxious stimulus that
threatens homeostasis (Fricchione & Stefano, 1994; Koob, 1999). The term anxiety is
traditionally used to describe a subjective feeling reported by humans, often in response to actual
or perceived stressors. In fact the dictionary definition of anxiety is: “an abnormal and
overwhelming sense of apprehension and fear often marked by physiological signs (as sweating,
tension, and increased pulse), by doubt concerning the reality and nature of the threat, and by selfdoubt about one's capacity to cope with it.” (Merriam-Webster, 1987, p93). However, in
scientific literature, the two terms are increasingly being used interchangeably. For example, drugs
that reduce stress responding in animals are often referred to as ‘anxiolytic’ and those that
increase stress responding are frequently called ‘anxiogenic’. As the subjective ‘feeling’ of anxiety
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cannot be measured in animals, these terms, as they are used throughout this dissertation, are
meant to refer to a measurable decrease or increase (respectively) in the physiological and/or
behavioral response to a stressor.
Stressors
Several stimuli are stressors in the rat. These include foot shock, (Amat, Matus-Amat,
Watkins, & Maier, 1998; Saphier, Farrar, & Welch, 1995), restraint (Kirby, Chou-Green, Davis,
& Lucki, 1997; Nonaka, 1999; Singewald, Kaehler, Hemeida, & Philippu, 1997), noise stress
(Saphier et al., 1995), injections of various substances (Adell, Casanovas, & Artigas, 1997;
Rodriguez Echandia, Broitman, & Foscolo, 1983), forced swimming, heat or cold stress, handling
(Adell et al., 1997; Kirby et al., 1997), tail pinch (Boutelle, Zetterstrom, Pei, Svensson, & Fillenz,
1990; Hawkins et al., 1999; Kirby et al., 1997; Pei, Zetterstrom, & Fillenz, 1990), and placement
in an open field (Onaivi, Bishop-Robinson, Darmani, & Sanders-Bush, 1995). While the nature of
the stressor may vary, the physiological and behavioral reactions that animals display share many
common features (Chrousos & Gold, 1992).
Physiological Responses to Stress
Sympathetic Nervous System. The fight-or-flight response, as it was called by
physiologist Walter Cannon, refers to activation of the sympathetic nervous system in response to
a stressor. This response includes a number of physiological changes that prepare the body for
activity. Epinephrine and norepinephrine are released by the adrenal medulla (Chrousos et al.,
1992). The release of these transmitters has several effects on the body, including mobilization of
nutrients from bodily stores, increased cardiac output, and redirection of blood flow away from
the dermis, gastrointestinal tract, other internal organs and the extremities toward the major
skeletal muscle groups (Chrousos et al., 1992). Increased circulation and nutrient availability to
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the skeletal muscles prepares the body for quick and vigorous action in response to threatening or
stressful stimuli. Sympathetic activation also results in bronchial relaxation, epocrine gland
stimulation, and salivary gland inhibition, all of which further prepare the body for activity
(Chrousos et al., 1992).
Hypothalamic-Pituitary-Adrenal (HPA) Axis. When a stressor activates the hypothalamicpituitary-adrenal axis, a chemical cascade occurs that helps prepare the organism to react to the
stressor (Raghavendra & Kulkarni, 2000a). The response starts in the hypothalamus with the
release of corticotropin releasing factor (CRF) (Dohms & Metz, 1991; Owens & Nemeroff,
1991). CRF, in turn, stimulates the anterior pituitary gland to release adrenocorticotropic
hormone (Jorgensen, Knigge, Kjaer, Vadsholt, & Warberg, 1998) into the blood stream (Dohms
et al., 1991; Jezova, Ochedalski, Glickman, Kiss, & Aguilera, 1999; Owens et al., 1991). When
the adrenocorticotropic hormone reaches the adrenal cortex, glucocorticoids, such as cortisol, are
released into the blood stream (Dohms et al., 1991). Cortisol, in turn, increases the amount of
glucose in the blood, enhances cardiac output, and stimulates energy expenditure (Dohms et al.,
1991; Laue, Loriaux, & Chrousos, 1988). HPA axis activation is necessary for appropriate
responding to a stressor (Lopez, Akil, & Watson, 1999), and deregulation of HPA axis activity
has been implicated in both depression (Curtis & Valentino, 1994; Deakin, 1991; Nemeroff, 1988)
and anxiety (Nemeroff, 1992).
Neurotransmitter Activity. 3,4-dihydroxyphenylethylamine (dopamine) is the precursor to
norepinephrine and exerts similar effects to norepinephrine in the periphery, such as increased
blood pressure and cardiac output. Dopamine, another neurotransmitter in the CNS (Dishman,
1997; Inoue, Tsuchiya, & Koyama, 1994), is well known for its involvement in centrally
controlled activities such as extra-pyramidal movement (i.e., fine motor skills), regulation of
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eating and sexual behavior, reward, learning processes, and psychiatric disorders like
schizophrenia (Hoebel, 1985).
Dopamine has been implicated in the stress response in several ways. Activation of
dopamine pathways has been observed as a consequence of a number of the physical stressors
discussed above (Kalivas, Duffy, & Eberhardt, 1990). Microdialysis studies have revealed that
stress increases dopamine and its metabolites in several brain sites (Inoue et al., 1994). Increases
and decreases in stress behavior occur with administration of dopamine agonists and antagonists,
respectively.
Gamma-aminobutyric acid (GABA) is a neurotransmitter found in the mammalian nervous
system that was originally recognized for its anticonvulsant activity in the CNS (Corda, Lecca,
Piras, Di Chiara, & Giorgi, 1997). GABA has also been found to be of relevance in the stress
response. Microdialysis studies show increases in GABA in the basal ganglia, cerebral cortex and
striatum after application of acute physical stressors (Otero Losada, 1989).
5-HT involvement in the physiological response to stress is discussed at length below (see
section 5-HT and Physiological Responses to Stress).
Behavioral Responses to Stress
Many behavioral reactions to stressful stimuli have been reported for rats and other
mammals. In some cases, a stressor can elicit a uniform behavioral profile. For example, in
response to the application of a tail pinch, rats typically perform oral stereotypies such as eating
and gnawing food, drinking, and licking both themselves (grooming) and other objects in the
environment (Levine & Morley, 1981; Hawkins et al., 1999). In other instances, a single stressor
can elicit a range of behaviors from an animal. When placed in the open field, rats show significant
increases in freezing, rearing on the hind legs, sniffing, performing quick rotations of the body,
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urinating, defecating, and spending more time near the wall of the open field (Kalin & Takahashi,
1990; Koob et al., 1993).
HPA Axis Involvement. Much research has addressed the role that increased HPA axis
activity plays in mediating behavioral reactions to stressful stimuli. The release of CRF during
stress has been linked to increases in locomotion and grooming, suppressed sexual behavior, and
abnormal sleeping patterns (De Wied & Croiset, 1991; Koob, 1999; Levine et al., 1981;
Nemeroff, 1988). Britton, Koob, Rivier, and Vale (1982) reported increased grooming and
avoidance behaviors after central administration of CRF and placement of the animal in an open
field. CRF is also linked to decreased food intake during stress. The number of approaches to
food and the amount of food ingested decrease in rats that receive CRF (De Wied et al., 1991),
and CRF has been shown to reduce food intake in animals that have been injected with substances
that normally induce eating (Gosnell, Morley, & Levine, 1983). There is strong evidence that this
reduction of food intake is a direct effect of CRF, as this effect persists in animals with lesioned
adrenal glands, indicating that CRF’s influence on other peptides (like ACTH) is not involved in
the suppression of eating (Levine & Levine, 1989). CRF has also been reported to directly
influence freezing behavior by activating the locus coeruleus. Swiergiel, Takahashi, Rubin, and
Kalin (1992) reported that injection of the CRF receptor antagonist alpha-helical CRF 9-41
reduced freezing behavior induced by foot shocks.
Neurotransmitter Involvement. Administration of different transmitter substances
(agonists/antagonists) often leads to observable changes in behavioral stress responding. For
example, central injections of the GABA agonist, muscimol, result in significantly increased stress
behavior in rats (Hawkins et al., 1999). However, there is some evidence that enhanced activity
at the same GABA receptor (subtype A) that muscimol stimulates can reduce stress responding
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(Corda et al., 1997). Dopamine has also been shown to increase stress responding in animals. It
appears that these two transmitter systems (dopamine and GABA) interact during stress, such that
the increase in responding to stress observed after administration of a GABA agonist can be
prevented with the co-administration of a dopamine antagonist (Hawkins et al., 2000).
5-HT is another neurotransmitter that is known to play a significant role in stress
responding. The evidence for the influence of 5-HT in physiological and behavioral responses to
stress is discussed at length in the following section.
5-HT Involvement in Stress Responding
5-HT and Physiological Responses to Stress
HPA Axis and Sympathetic Nervous System. 5-HT is reported to be a potent stimulator
of CRF release via its effect on the periventricular nucleus of the hypothalamus (Jorgensen et al.,
1998). Bell, Butz, and Alper (1999) found that the 5-HT2A/C agonist DOI injected into the
periventricular nucleus increased blood pressure and heart rate by stimulating the release of CRF.
Lesions of serotonergic neurons in the CNS lead to decreased or abolished ACTH release
(Chaouloff, 1993; Owens et al., 1991).
Stimulation or antagonism of 5-HT receptors has been shown to influence the release of
hormones from the anterior pituitary, including ACTH, during stress (Jorgensen et al., 1998).
Independent of CRF release, 5-HT is able to directly stimulate the anterior pituitary to release
ACTH (Chaouloff, 1993). However, the influence of 5-HT on the HPA axis is not consistent.
Exemplifying this ambiguity, Welch and Saphier (1994) reported that the 5-HT agonist DOI
(administered both peripherally and centrally) increased plasma ACTH, as did high doses of the 5HT antagonist ketanserin (administered ICV). Adding to this inconsistency, there is some
evidence that the influence of 5-HT varies depending on the type of stressor with which an animal
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is confronted. Chaouloff (1993) reported that animals with lesions of the 5-HT neurons in the
hypothalamus exhibited lower than normal corticosterone levels after exposure to photic stress or
conditioned fear stress (as would be predicted), but the corticosterone levels were normal
following exposure to ether or acoustic stress. Thus, it appears that some stressors activate the
HPA axis via central 5-HT mechanisms, while other kinds of stressors activate the axis without
affecting 5-HT release.
Although the exact nature of 5-HT’s role in the stimulation of the autonomic nervous
system is unclear, 5-HT does seem to be involved in the sympathetic nervous system response to
stress. For instance, 5-HT is taken up with norepinephrine by sympathetic nerves (Watling,
2001). Additionally, 5- HT is known to be involved in the inhibition of norepinephrine containing
neurons in the locus coeruleus, a brain area that is active during stress responding (Sinner,
Kaehler, Philippu, & Singewald, 2001).
CNS. Several studies have investigated the effects of different stressors on the amount of
5-HT or a metabolite of 5-HT, 5-HIAA, in various areas of the brain. Restraint stress has been
shown to increase levels of both 5-HT and 5-HIAA in the locus coeruleus (Singewald et al.,
1997), hippocampus (Bonnin, Grimaldi, Fillion, & Fillion, 1999; Boutelle et al., 1990;
Vahabzadeh & Fillenz, 1994), cortex, hypothalamus, and substantia nigra (Bonnin et al., 1999).
Similarly, tail pinch has been shown to increase 5-HT in the striatum (Kirby et al., 1997),
hippocampus (Boutelle et al., 1990; Kirby et al., 1997; Pei et al., 1990; Vahabzadeh et al., 1994),
and frontal cortex (Pei et al., 1990).
CNS Pathways. As indicated above, pathways from the DRN are thought to be activated
when animals are stressed, however there is evidence for differential activation depending on
whether the type of stress the animal is subjected to activates a panic or an anxiety reaction.
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Deakin and Graeff distinguish between types of stressors by classifying them as either anxiety
provoking (from distal threat) or panic provoking (from proximal physical stressors). There is
evidence that 5-HT plays a dichotomous role in behaviors evoked by these two types of stressors.
The DRN pathway to the amygdala appears to be important in the response to anxiety. If
5-HT activity in the amygdala is decreased, anxiolytic effects are seen (Graeff, 1993), and
research shows that severing the connections between the DRN and the amygdala abolishes fear
responding in animals. These findings are supported by evidence that microinjections of 5-HT
antagonists directly into the amygdala and hippocampus prevent the typical fear response in
animals (Deakin, 1991; Graeff, 1994).
In panic reactions, the DRN connection to the periaqueductal gray is important.
Serotonin activation of the DRN occurs with stimuli that are predictive of noxious events, and
leads to escape and avoidance behavior in animals. In contrast to the anxiolytic effect described
above with decreased 5-HT activity in the amygdala, increasing serotonin activity in the
periaqueductal gray produces anti-panic effects (Graeff, 1993; Graeff et al., 1997).
These findings support a contradictory role for 5-HT in anxiety and panic and seem to be
in agreement with at least some clinical research. For example, in humans the 5-HT antagonist
ritanserin has been shown to reduce anxiety in generalized anxiety disorder, but to increase the
symptomology of panic disorder (Graeff, 1993). Graeff, Zuardi, Giglio, Lima Filho, and Karniol
(1985) reported that metergoline, another 5-HT antagonist, increased reports of anxiety in healthy
human participants. Silva, Hetem, Guimaraes, and Graeff (2001) and Graeff et al. (2001) both
reported that nefazadone, a 5-HT2A antagonist, reduces conditioned anxiety, but increases
unconditioned fear (i.e., panic). One group of participants was given nefazadone and tested after
undergoing skin conductance conditioning to white noise (an aversive stimulus), while another
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group was given nefazadone then tested after performing a public speaking task. Both groups
were asked to rate their subjective feelings of anxiety during the testing. Compared to a placebo
control group, the conditioned anxiety group experienced reduced changes in skin conductance as
well as reduced subjective report of anxiety. The participants in the public speaking group who
were given nefazadone, on the other hand, experienced increased feelings of anxiety compared to
those participants who received placebo.
Graeff et al. (1997) describe this hypothesis of anxiety/panic reactions by considering
anxiety a learned response, and panic an innate, fight-or-flight-like reaction. This definition of
panic, reaction to a proximal threat causing activation of the fight-flight response, can be likened
to the response to physical stressors seen in animals described in detail above. When considered in
the context of this hypothesis, projections from the DRN to the periaqueductal gray would most
likely become active with the application of an inescapable stressor like tail pinch or open field.
Neurotransmitters. In addition to influencing activity in specific brain structures such as
the amygdala and periaqueductal gray discussed above, 5-HT also exerts complex effects on the
release of other neurotransmitters (such as dopamine and GABA) in the CNS.
Activation of 5-HT2A receptors in the nucleus accumbens is correlated with larger and
longer-lasting increases of dopamine in that brain area (Yan, Reith, & Yan, 2000), and Pehek,
McFarlane, Maguschak, Price and Pluto (2001) demonstrated the converse effect of 5-HT in the
prefrontal cortex – application of a 5-HT2 antagonist decreased dopamine release. However, Di
Matteo, Di Giovanni, Di Mascio, and Esposito (2000) found that with systemic injection of the 5HT2C agonist RO 60-0175, dopamine release and firing rate of dopamine neurons in the ventral
tegmental area were decreased.
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Some researchers (Goudreau, Wagner, Lookingland, & Moore, 1994) have also observed
a modulatory influence of 5-HT on dopamine release in the pituitary, indirectly through its
influence on GABA transmission in the CNS. 5-HT2 activation increases transmission and
synaptic potentials of GABAergic neurons in the hippocampus (Lee, Dixon, & Pinnock, 1999).
Abi-Saab, Bubser, Roth, and Deutch (1999) also found that the 5-HT2A/C receptor agonist DOI
activated GABA neurons, leading to increased extracellular GABA in the prefrontal cortex.
The influence of neurotransmitter activity on behavioral responding to stress in both
humans and animals has been an increasingly popular area of study for the past 20 years. Systemic
and central injections of various serotonin agonists and antagonists have resulted in measurable
changes in stress-induced behaviors. Below, the direct role of 5-HT in stress responding is
discussed at length.
5-HT and Behavioral Responding to Stress
While many studies of 5-HT and stress responding are in vivo dialysis studies describing 5HT release in different regions of the brain during stress, such as the hippocampus (Kirby et al.,
1997; Jorgensen et al., 1998; Rueter, Fornal, & Jacobs, 1997; Vahabzadeh et al., 1994; Rueter &
Jacobs, 1996), the prefrontal (Mendlin, Martin, & Jacobs, 1999; Rueter et al., 1997) and frontal
cortex, the corpus striatum (Kirby et al., 1997; Mendlin et al., 1999; Rueter et al., 1997), the
locus coeruleus (Singewald et al., 1997; Sinner et al., 2001), and the amygdala (Rueter et al.,
1996), many have described behavioral changes following manipulation of 5-HT systems as well.
The 5-HT1, 2, 3, & 4 receptor families have all been implicated in stress responding. 5-HT1A
receptor stimulation in the CNS has been shown to increase locomotion in a novel environment
(Carli & Samanin, 1988) and to reduce the ACTH response to acoustic and conditioned fear
stressors (Saphier et al., 1995). Peripheral stimulation of the same receptor reduced immobility to
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forced swimming stress (Moser & Sanger, 1999). Increases in locomotion and gnawing have
been seen with either central or peripheral administration of PBG, a 5-HT3 receptor agonist.
Antagonizing both 5-HT3 and 5-HT4 receptors with tropisterone has resulted in reduced ACTH
secretion to both restraint and ether stress (Jorgensen et al., 1998).
Manipulating 5-HT activity at the 5-HT2A and 2C receptors during stress has been shown
to affect behavioral responses including feeding and ingestive behavior (De Vry & Schreiber,
1997), immobility (Redrobe & Bourin, 1997), sexual behavior (Gorzalka, Hanson, & Brotto,
1998), and grooming behavior (Scalzitti, Cervera, Smith, & Hensler, 1999).
Although evidence exists that serotonin is involved in the etiology of these and other stress
induced behaviors, the exact nature of the influence is not completely clear – as administration of
5-HT agonists and antagonists has resulted in both increases and decreases in stress related
behavior. That is, 5-HT can act as both an anxiolytic and an anxiogenic substance. These findings
are presented in the following two sections.
5-HT as Anxiogenic. Two lines of evidence have been reported in support of 5-HT as an
anxiogenic neurotransmitter: 1) administration of compounds that produce an increase in 5-HT
release, resulting in increases in behavioral responding to stress, and 2) administration of
compounds that produce a decrease in 5-HT release, resulting in decreases in stress responding.
Reports of both types are presented below.
Several drugs that increase 5-HT release have been reported to produce anxiogenic
effects. Intraperitoneal injection of serotonin agonists zimelidine, fluoxetine, quipazine, and
MK212 increased avoidance behavior in rats (Kshama, Hrishikeshavan, Shanbhogue, &
Munonyedi, 1990). Central and peripheral administration of the 5-HT2B/2C agonist m-CPP has
also been shown to increase avoidance behavior in the elevated T-maze (Zanoveli, Nogueira, &
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Zangrossi, Jr., 2003) and to reduce open-arm entries (Gibson, Barnfield, & Curzon, 1994) and
locomotion (Durand, Mormede, & Chaouloff, 2003) in the plus-maze. The SSRI paroxetine has
also produced anxiogenic effects in the elevated plus-maze, resulting in a decrease in open-arm
entries, time spent in open arms, and number of line crosses (Koks et al., 2001). Stimulation of
the 5-HT1B (Lin & Parsons, 2002), 5-HT2A, and 5-HT2C (Setem, Pinheiro, Motta, Morato, &
Cruz, 1999) receptors have also produced anxiogenic effects in the plus-maze.
There are two ways of producing a net decrease in 5-HT release in the synapse: to
administer a 5-HT antagonist, or to administer an autoreceptor agonist. The m-CPP findings
reported above were attenuated by both administration of 5-HT antagonists (Gibson et al., 1994)
and autoreceptor agonists (Zanoveli et al., 2003). Another study reports that mice display
anxiolytic responses (increased entries and time spent in open arms) when given the autoreceptor
agonist MKC-242 (Sakaue et al., 2003). Systemic injection of 5-HT antagonists
chlorophenylalanine, zacopride, GR 38032F, and propranolol resulted in reduced avoidance
behavior (Kshama et al., 1990), and other antagonists have been shown to increase grooming in
response to various stressors (Rodriguez Echandia et al., 1983).
5-HT as Anxiolytic. Like the evidence presented above, there are two main types of
reports that indicate an anxiolytic effect of 5-HT in stress responding: 1) administration of
compounds that produce an increase in 5-HT release, resulting in decreases in behavioral
responding to stress, and 2) administration of compounds that produce a decrease in 5-HT
release, resulting in increases in stress responding. Both types of evidence are reviewed below.
Studies have found that increasing 5-HT activity in general results in decreased behavioral
responding to stress. Amer, Breu, McDermott, Wurtman, and Maher (2004) report that peripheral
administration of the 5-HT precursor, 5-hydroxy-L-tryptophan, results in decreased food intake

21

during tail pinch stress and Blokland, Lieben, and Deutz (2002) found that tryptophan depletion
(which leads to decreased 5-HT availability) results in increased anxiety behavior in the open field.
Grimaldi, Bonnin, Fillion, Prudhomme, and Fillion (1999) reported blocking an endogenous
peptide that exerts an antagonistic effect at 5-HT receptors (i.e., resulting in a net increase in
activity at 5-HT receptors) resulted in an anxiolytic effect on behavior in the open field.
Others have performed more receptor-specific manipulations of 5-HT activity during
stress. Specifically, stimulating 5-HT2 receptors in animals has been reported to have anxiolytic
effects during exposure to various stressors. Aniracetam, a 5-HT2A agonist, has anxiolytic effects
in social interaction, elevated plus maze, and conditioned fear stress (Nakamura & Kurasawa,
2001). Similarly, dexfenfluramine and quipazine, both 5-HT2 agonists, reduce tail pinch induced
eating (Morley, Levine, Murray, Kneip, & Grace, 1982; Rowland & Souquet, 1989).
Alternatively, antagonizing 5-HT2 receptors has resulted in increased ultrasonic stress
vocalizations in rat pups (Olivier et al., 1998) and increased reports of anxious feelings in humans
(Graeff et al., 2001; Silva, Hetem, Guimaraes, & Graeff, 2001). While not direct evidence using a
specific antagonist, one study found that decreased sensitivity of 5-HT2 receptors caused by social
defeat resulted in increased anxiety behaviors in the elevated plus-maze (Benjamin et al., 1993).
Schreiber, Melon, and De Vry (1998) investigated which 5-HT receptors are involved in
the anxiolytic effects of the SSRIs by injecting different 5-HT receptor agonists and antagonists
(for activation or blockade of 5-HT1A, 1B/1D, 2A, 3, and 4 receptors) peripherally in rats and testing for
changes in ultrasonic vocalization to foot shocks. They found significant reductions in
vocalization with the 1A agonist 8-OH-DPAT, the 1B/1D agonist TFMPP, the 2A/C agonist DOI, and
the 2C agonist mCPP. Several of these effects were reversed with administration of receptorspecific antagonists. The anxiolytic effects of the SSRI paroxetine, however, were only reversed
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by the 5-HT2A antagonist MDL 100,907, leading the authors to conclude that the main pathway
through which this SSRI works is the 5-HT2A receptor. In support of this finding, Sanchez and
Mork (1999) reported that peripherally injecting a precursor of 5-HT or the 5-HT2A/C agonist DOI
reduced the ultrasonic vocalization induced by foot shocks in rats, and that the antagonist
ritanserin reversed this effect.
Onaivi et al. (1995) found that the 5-HT2A/C agonist DOI acted as both an anxiolytic and
an anxiogenic (depending on the dose administered) in Hooded rats and ICR mice in the elevated
plus-maze. At doses of 2.5 mg/kg or below, a significant increase was observed in the amount of
time animals spent in the open arms of the maze, while doses above 2.5 mg/kg resulted in
significantly less time spent in the open arms. The anxiolytic effect of the lower doses of DOI was
reversed by the 5-HT2 antagonist ketanserin. Interestingly, in two other strains of mice, different
results were found. In the DBA/2 strain, DOI (regardless of dose) decreased the amount of time
spent in the open arms of the maze, but in the C57/BL6 strain, the opposite effect occurred and
DOI only increased the amount of time spent in the open arms.
Both Mora, Netto, and Graeff (1997) and Zangrossi, Jr. et al.(2001) reported that
administration of 5-HT2 agonists decreases fear and escape behaviors in animals. Mora et al. gave
rats peripheral injections of the 5-HT2C agonists mCPP and TFMPP, finding that TFMPP
significantly inhibited escape behavior in the elevated T-maze. Zangrossi et al., on the other hand,
injected DOI centrally in the dorsal periaqueductal gray and also found that latency to escape was
enhanced in the elevated T-maze. Additionally, Setem et al. (1999) reported that the 5-HT2A
antagonist SR 46349B injected intraperitoneally resulted in significant displays of anxiety behavior
in rats placed in the elevated plus-maze. Animals given this drug spent less time in open arms,
scanning, and exploring, all of which are behavioral indicators of anxiety.
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Unlike many of those reported above, some studies have included central injections,
allowing for some hypothesis on sites of anxiolytic action of 5-HT in the CNS. Using the elevated
plus-maze, Audi, de Oliveira, and Graeff (1989) reported that increasing 5-HT activity by
injecting propranolol, a 5-HT1A (autoreceptor) antagonist, into the dorsal periaqueductal gray of
rats resulted in increased open arm entries. The authors also injected ritanserin, a 5-HT2
antagonist, into the same brain area and were able to block the propranolol effect. The
combination of these two findings led Audi et al. (1989) to hypothesize that the increase in 5-HT
in the dorsal central gray resulting from the blockade of the autoreceptor was subsequently acting
on 5-HT2 receptors to produce the anxiolytic effect. In a later study, Audi, de Oliveira, and
Graeff (1991) injected the same 5-HT1A antagonist into the dorsal periaqueductal gray and were
able to elaborate upon the previously reported findings. Propranolol injected into the dorsal
periaqueductal gray increased rats’ open arm entries, not just total arm entries, indicating that this
is a true anxiolytic effect, not just a byproduct of some nonspecific increase in activity. While this
effect was not reversed by ritanserin as it was in the previous (1989) study, it was blocked by
ketanserin, another 5-HT2 antagonist that has an affinity for 5-HT2 receptors that is approximately
70 times greater than that of ritanserin (Hoyer, 1988).
In addition to tests of anxiolytic effects of centrally administered drugs in the open-armed
plus or T-maze, researchers have tested the anxiolytic profile of many centrally injected
serotonergic drugs using another paradigm: aversive brain stimulation. In another investigation of
the dorsal periaqueductal gray, Nogueira and Graeff (1995) reported that administration of the 5HT2A/C agonist DOI into this area in rats decreased the aversiveness of stimulation of that area, an
effect that was reversed with pre-administration of a 5-HT2A antagonist, spiperone. Schutz, de
Aguiar, and Graeff (1985) reported that injecting 5-HT itself directly into the dorsal
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periaqueductal gray, or peripherally, increases animals’ threshold for aversive brain stimulation as
indicated by significant decreases in escape behaviors with stimulation. This effect was increased
by zimelidine, a 5-HT uptake inhibitor, and was reversed by both metergoline and ketanserin.
Others have produced similar findings. Melo and Brandao (1995) found that injecting zimelidine
or the 5-HT2 agonist alpha-methyl-5-hydroxytryptamine into the inferior colliculus resulted in a
longer latency and fewer attempts to stop aversive electrical stimulation of this area.
Ambiguity of 5-HT Influence on Stress Responding. In addition to the evidence outlined
in the two previous sections supporting both an anxiolytic as well as an anxiogenic role for 5-HT
in stress responding, a single study by Olivier et al. (1998) demonstrates the ambiguity of 5-HT’s
influence on anxiety and stress. In a 1994 review, Olivier et al. (1994) reported that several 5HT1A autoreceptor agonists (buspirone, ipsapirone, gepirone, flesinoxan) were found to have
anxiolytic properties. In 1998, Oliver et al. tested several substances with 5-HT receptor affinity
in two different stressful temperature conditions: the warm and the cold plate. While the
anxiolytic properties of the autoreceptor agonists buspirone, ipsapirone, and flesinoxan were
reproduced in both temperature conditions, causing reductions in ultrasonic vocalization, the
authors reported significant anxiolytic effects for autoreceptor antagonists (e.g., NAN-190) as
well. Further, the overall pattern of results was quite variable, with one 5-HT uptake inhibitor
(fluvoxamine) reducing ultrasonic vocalization in both conditions, another (clomipramine) only
reducing anxiety behavior in the warm stimulus condition, and the 5-HT2 antagonist ketanserin
increasing ultrasonic vocalization with the cold plate stimulus only.
In addition to type of stressor, the gender of the animal has also been reported to influence
the way 5-HT impacts stress responding. One study showed that injecting ovariectomized female
rats with estradiol benzoate alone or together with progesterone prevented the inhibition of
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lordosis behavior induced by central injection of a 5-HT1A receptor agonist, and progesterone (but
not estradiol benzoate) prevented the restraint stress-induced reduction of lordosis behavior
(Truitt et al., 2003). Dominguez et al. (2003), found more 5-HT activity as indicated by higher
levels of the 5-HIAA metabolite in the female DRN, but not the MRN, when compared to male
animals. The same group also reported that female rats exhibit more stress-induced behaviors than
males when placed in the elevated plus maze, but only on the first day of diestrus, when animals
are unresponsive to estrogen and progesterone levels are rising. Another report indicates that
chronic restraint stress increases the amount of 5-HT in the hippocampus of female, but not male
rats; this increase, along with changes in other neurotransmitter and hormonal systems, may be
related to the protection against the detrimental effects of stress on certain memory tasks
observed in female, but not male animals (Luine, 2002). Because of these sex-based differences,
most research, including this dissertation, uses only male animals in studies of stress responding.
Summary
There are several reports that support 5-HT as an anxiogenic neurotransmitter as well as
many reports that support the anxiolytic effects of 5-HT on behavioral responding to stress. The
findings outlined in the “5-HT as Anxiolytic” section above tend to support Graeff and Deakin’s
theory that with the application of actual, proximal stressors such as foot shocks, aversive brain
stimulation, and placement in an open field, stress responding is decreased with administration of
5-HT agonists, and that this decrease is prevented with concomitant administration of 5-HT
antagonists. However, as outlined in the section, “Ambiguity of 5-HT influence on Stress
Responding,” behavioral responses to stressors of a similar nature (e.g., hot/cold plate) can be
influenced in different ways by both agonists and antagonists. Further study, of different stressors
as well as different 5-HT agents, is needed to clarify the place of 5-HT in stress responding.
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Purpose of the Present Study
Based on the literature reviewed above, one can conclude that 5-HT influences stress
responding in a number of ways depending on the strain of rat used, the type of agent
administered (i.e., what receptor affinity it has, whether it is an agonist or antagonist, etc.), the
dose of the agent administered, the route of administration, as well as the type of stressor
employed. To date, no published report has investigated the influence of centrally and/or
peripherally administered 5-HT2a/c agonist DOI or the 5-HT2a/c antagonist ketanserin on behaviors
evoked by tail pinch or open field stress.
The purpose of the reported experiments was two-fold. First, to investigate the role of 5HT2A/C receptors in the behavioral response to two types of stressors in the rat: tail pinch and the
open field. Second, to help clarify any differences in the central vs. peripheral influence of 5-HT
on stress responding.
Hypotheses
1. DOI will reduce stress responding in both the tail pinch and open field conditions when
injected either a) peripherally, b) centrally, or c) both simultaneously.
2. Ketanserin may a) increase behavioral responding to stress when injected alone, and will b)
reverse the reduction in behavioral responding from injection of DOI.
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METHODS
Five separate, but related experiments were conducted to test the above hypotheses. Each
is described below in the section entitled Experiments. Refer to Table 1 for the basic tenets of
each.
Drugs
5-HT2A & 2C Agonist
(+/-)-1-(2,5-dimethoxy-4-iodophenyl)-2 aminopropane (DOI) acts as a potent agonist at
the 5-HT2A and 2C receptor subtypes (Figure 2). DOI is classified as a phenethylamine
hallucinogen (Liu, Jolas, & Aghajanian, 2000) that, according to information supplied by the
manufacturer (Sigma/RBI), readily crosses the blood brain barrier. While not used in research or
treatment of human subjects (except ex vivo tissue studies e.g., Bax, Heuven-Nolsen, Bos,
Simoons, & Saxena, 1992; Serres, Azorin, Valli, & Jeanningros, 1999), DOI has been used in
many studies of 5-HT influence on physiological and behavioral stress responding in animals, as
described in detail above.
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Figure 2: DOI Chemical Structure (from: http://infonew.sigma-aldrich.com)
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5-HT2A & 2C Antagonist
Ketanserin (KET) is an antagonist at the 5-HT2A and 2C receptors (Figure 3). KET was
originally used as an antihypertensive agent (Awouters, 1985) and has also been used to treat
nociceptive disorders (Alhaider, 1991; Klimiuk et al., 1989) and Raynaud’s syndrome (to increase
circulation to the extremities) (Dormandy, Berent, & Downes, 1988).
As indicated by the research described above, KET is commonly used in stress research.
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Figure 3: Ketanserin Chemical Structure (from: http:// info new.sigma-aldrich.com)

Pilot Work
The route of administration and specific doses of both drugs were determined using the
literature as a guide (e.g., Jorgensen et al., 1998; Onaivi et al., 1995) as well as pilot work
employing a range of doses of both drugs in our laboratory. The 30-minute latency between the
injection of peripherally administered drugs and testing is based on our pilot work where animals
were tested 0, 30, and 60 minutes after injection, as well as guidance from the literature (e.g.,
Diaz-Veliz et al., 1997; Nic Dhonnchadha et al., 2003).
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Experiments
Experiment 1: Peripheral DOI
This experiment was designed to test part ‘a’ of hypothesis one, that peripherally injected
DOI will reduce stress responding to tail pinch and open field stressors.
Animals. Forty-eight male Sprague-Dawley rats, approximately eight weeks of age, were
used for this experiment. Animals were obtained from the Division of Laboratory Animal
Medicine, Louisiana State University. Animals were housed in individual plastic cages with food
and water available 24 hours/day. The room where the animals were housed was maintained at a
temperature of 22°C and overhead lighting was on a 12-hour light/dark cycle, on at 0700 hr.
Drug. DOI was obtained from SIGMA/RBI (Sigma-Aldrich, Inc.). It was kept in its
original container, in the dark, at room temperature. Each testing day, drug was weighed out and
the appropriate volume of sterile normal saline was added to reach the desired concentration.
Experimental Group Assignment. Before the collection of data, animals were randomly
assigned to a drug or control group. In this experiment, the groups consisted of saline control (n
= 15), 0.1 mg/kg DOI (n = 9), 0.5 mg/kg DOI (n = 12), and 1.0 mg/kg DOI (n = 12).
Experiment 2: Central DOI
This experiment was designed to test part ‘b’ of hypothesis one, that centrally injected
DOI will reduce stress responding during tail pinch and placement in the open field.
Animals. Fifty-five animals were obtained from the same colony and were the same sex
and approximate age as previously described. Housing conditions were as described above.
Drug. DOI was obtained from Sigma/RBI (Sigma-Aldrich, Inc.). It was dissolved using
sterile water and distributed into aliquots. Aliquots were lyophilized and stored at 0°C until just
prior to testing. For injection, the drug was reconstituted with sterile 0.9% saline.
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Experimental Group Assignment. Animals were randomly assigned to one of 4 groups:
saline control (n = 17), 20 µg (n = 13), 100 µg (n = 18), or 200 µg (n = 14) of DOI.
Surgery. In order to receive ICV injections, animals underwent stereotaxic surgery for
implantation of permanently indwelling bilateral cannulae. Animals were anesthetized with
ketamine (90 mg/kg i.m.) and xylazine (5 mg/kg i.m.). Once the anesthetic had taken effect, the
top of an animal’s head was shaved and the head was mounted on the stereotaxic apparatus. The
surface of the skull was exposed and irrigated with approximately 0.25 ml of a
bupivacaine:lidocaine mixture to reduce postoperative pain. Stainless steel anchor screws were
inserted into the skull and permanently indwelling, stainless steel guide cannulae were implanted
0.0 mm anterior to bregma, +/-1.6 mm lateral from midline, and –3.0 mm ventral from dura.
Dental acrylic was used to hold the cannulae in place and prevent the recovered animal from
disturbing the implant. Animals were closely monitored following surgery, until they emerged
from anesthesia. Animals were given five days following the completion of the surgical procedure
to recover before experimental testing began. This surgical protocol was reviewed and approved
by the Louisiana State University Institutional Animal Care and Use Committee (protocol #99115).
Experiment 3: Central + Peripheral DOI
This experiment was designed to test part ‘c’ of hypothesis one that simultaneous central
and peripheral injections of DOI will reduce stress responding in both the tail pinch and open field
conditions.
Animals. Twenty-three male animals were used in this experiment. They were obtained
from the same colony, were within the same age/weight range, and were housed as described
above.
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Drug. DOI was used as described in Experiment 1 and Experiment 2, above.
Experimental Group Assignment. Two groups were employed in this experiment: a saline
control that received both a central and a peripheral injection of saline (n = 13) and a drug group
that received a 200 µg central injection of DOI and a 0.1 mg/kg peripheral injection of DOI (n =
15).
Surgery. Animals in this experiment underwent surgery as described above for
Experiment 2.
Experiment 4: Peripheral KET
This experiment was designed to test part ‘a’ of hypothesis two, that administration of
KET may increase stress responding during tail pinch and in the open field.
Animals. Thirty-one male rats were used for this portion of the study. Animals were
obtained from the same colony, were within the same age/weight range, and were housed as
described above.
Drug. KET was obtained from Sigma-Aldrich and stored according to the manufacturer’s
direction, at 0°C. Drug was weighed prior to testing and diluted in sterile 0.9% saline.
Experimental Group Assignment. Animals were randomly assigned to one of three drug
groups: 0.5 mg/kg KET (n = 11), 2.5 mg/ KET (n= 10), and 5.0 mg/kg KET (n = 10). The
control group for this experiment was shared with Experiment 1, as the two experiments had
identical injection and testing protocols.
Experiment 5: Peripheral DOI + Peripheral KET
This experiment was designed to test part ‘b’ of hypothesis two, that KET will reverse the effect
of DOI, and prevent the reduction in behavioral responding to tail pinch and open field stressors.
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Animals. Ninety-six male animals were used in this experiment. Animals were obtained
from the same colony, used within the same age/weight range, and housed as described above.
Drug. Both DOI and KET were obtained, stored, and prepared for injection as previously
described.
Experimental Group Assignment. Animals were randomly assigned to one of six groups:
double saline control group (n = 16), 0.5 mg/kg DOI + saline (n = 16), 1.0 mg/kg DOI + saline (n
= 16), 5.0 mg/kg KET + saline (n = 16), 0.5 mg/kg DOI + 5.0 mg/kg KET (n = 16), and 1.0
mg/kg DOI + 5.0 mg/kg KET (n = 16).
Table1: Design for all 5 Experiments

Injection
Type
N
Drug

Experiment
1
Peripheral

Experiment
2
Central

48
DOI
Saline
0.1 mg/kg
0.5 mg/kg
1.0 mg/kg

55*
DOI
Saline
20 µg
100 µg
200 µg

Experiment
3
Peripheral +
Central
23*
DOI
Saline
200 µg + 0.1
mg/kg

Dose

Experiment
4
Peripheral
31
KET
0.5 mg/kg
2.5 mg/kg
5.0 mg/kg

Experiment
5
Double
Peripheral
96
DOI + KET
Saline
DOI:
0.5 + saline
1.0 + saline
KET:
5.0 + saline
Both:
0.5 DOI +
5.0 KET
1.0 DOI +
5.0 KET

*Number represents post-histology n.
General Procedure
Rater Training Criterion
Data collectors were trained to 80% accuracy on the measurement of all dependent
measures. Training was conducted prior to the collection of data using animals that were not
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included as subjects. Data collectors were trained to properly handle the animals, apply the tail
pinch stressor, and collect behavioral data. Each collector was required to measure every
behavior in two consecutive trials to at least 80% concordance with another (previously trained)
rater on both trials.
Injections
Single Peripheral Injection Procedure: Experiments 1 & 4. Animals in Experiments 1 and
4 were removed from their home cage, restrained by hand and administered a subcutaneous
injection at the back of the neck. Animals were weighed a few minutes prior to injection and all
injections were given at a volume of 1.0 ml per kg of body weight. Following injection, animals
were returned to their home cages for a period of 30 minutes prior to being placed in the testing
cage and subjected to the tail pinch stressor.
Single Central Injection Procedure: Experiment 2. Animals were removed from their
home cages and restrained by hand. Stylets placed in the guide cannulae (to prevent blockage
during the post-operative recovery period) were removed and sterile injectors were inserted into
the guide cannulae. The injector tip extended 1.0 mm past the ventral end of the cannula.
Injectate was administered simultaneously to the lateral ventricles at a rate of 5.0 µl per minute
via polyethylene tubing connected to 100 µl syringes held in a Sage infusion pump. A total
volume of 10 µl was delivered to each ventricle over a two-minute period. The animals were
held, with injectors in place, for an additional one minute to allow the injectate to diffuse from the
site of injection. Animals were exposed to the tail pinch stressor immediately following the
injection procedure.
Central + Peripheral Injection Procedure: Experiment 3. The injection procedure for the
animals in experiment three had two phases. The first phase was identical to the peripheral
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injection procedure previously described. However, approximately 5 minutes before animals were
scheduled to go into the tail pinch testing cage (i.e., 25 minutes following peripheral injection),
they were removed from their home cages and given the ICV injection as described above.
Testing immediately followed the completion of the ICV injection.
Double Peripheral Injection Procedure: Experiment 5. Each animal in Experiment 5
received two consecutive peripheral injections. The injections were administered subcutaneously
at the back of the neck as described above. For the groups that received drug, animals received
the drug injection first and the saline injection immediately following. Animals that received two
injections of drug always received the DOI injection first and the KET second. As previously
described, animals were returned to their cages for 30 minutes before tail pinch testing.
Testing
All animals (Experiments 1-5) were tested for behavioral responding to stress under two
conditions. Testing was always conducted between 0900 and 1300, during the animals’ light
cycle. Animals were first subjected to a tail pinch stressor, where the animal was placed in a
suspended wire cage, the length of its tail guided though the bottom of the cage, and a clamp
(modified haemostatic forceps) was applied to the animal’s tail outside of the cage at a diameter
of 4.3 millimeters. The clamp was applied for a period of four minutes, during which animals
were observed for behavioral responses. When the four-minute testing period was over, the
clamp was removed and animals were returned to their home cage.
Forty-five minutes after injection (approximately ten minutes after the conclusion of the
tail pinch test), animals were again removed from their home cage and placed in the open field
apparatus for a four-minute observation period. This apparatus is an open topped box
constructed of clear Plexiglas with dimensions of 2’x2’x2’. The bottom of the box is demarcated
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into four 12” squares. A 75-watt light is positioned directly above the field. Following the testing
period, animals were returned to their home cage.
Rotarod
Twenty-four hours following stress testing (tail pinch and open field) animals were trained
on the rotarod apparatus. This instrument is a rotating stainless-steel drum (with a textured
surface for traction) 7.2 cm in diameter used to test for motor impairment. The training
procedure consisted of repeatedly placing the animal on the rotating drum (10 RPM) until it
remained on the drum for 30 consecutive seconds without losing balance.
Testing for motor impairment due to drug administration occurred 24 hours after the
animals were trained (that is 48 hours after testing in the stress conditions). Animals were
removed from their home cages and underwent the same injection procedure described above.
Thirty minutes following peripheral injection (Experiments 1, 4, & 5) or immediately following
central injection (Experiment 2 & 3), they were placed on the rotarod and were observed for
thirty seconds or until they fell from the rotarod, whichever occurred first.
Dependent Variables
Tail Pinch
The following seven variables were measured in the tail pinch condition:
1. Oral stereotopy with food was defined as the amount of time an animal engaged in
any oral behavior (i.e., licking, chewing, etc.) directed at lab chow.
2. Eating was recorded by subtracting the post-test weight of lab chow placed in the tail
pinch cage from the pre-test weight.
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3. Gnawing was defined as the amount of chow that was shredded, but not ingested, by
the animal during tail pinch. The shredded chow was collected beneath the testing
cage during tail pinch.
4. Grooming was measured as the amount of time the animal licked or combed any part
of its body or whiskers with its paws.
5. Oral stereotopy without food was recorded as the amount of time the animal
engaged in oral movement that did not involve food or self. This included licking and
biting of the cage and chattering of the teeth.
6. Vocalization was defined as the number of vocal emissions an animal made over the
course of the testing period.
7. Fecal boli were recorded as the number produced over the course of the testing
period.
An increase in any of the behaviors described above is indicative of increased stress
responding during exposure to a tail pinch stressor.
Open Field
The following six variables were measured in the open field condition:
1. A line cross was tallied each time an animal crossed with its front paws from one
quadrant to another in the open field box.
2. Rearing was defined as the number of times the rat simultaneously lifted both front
paws from the cage floor.
3. Freezing was recorded as the amount of time an animal displayed cessation of all
movement except breathing.
4. A headshake was recorded each time an animal vigorously shook its head.
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5. Wet dog shakes were recorded as the number of times the animal shook its head and
torso (in this case a headshake was not recorded).
6. Flat body posture was noted (presence or absence) and was defined as an elongated
posture in combination with a creeping gait.
In the open field, an increase in the amount of time spent freezing and a decrease in line
crosses or in rearing is indicative of increased stress responding. The remaining three variables
(head/ wet dog shakes and flat body posture) are not measurements of stress responding, but
rather of 5-HT2A/C receptor activity - an increase in these behaviors is indicative of increased
activity at the 5-HT 2A/C receptors.
Rotarod
The dependent measure for the rotarod test was latency to loss of balance. Each animal
was allowed to walk on the apparatus until it fell or the 30-second criterion was reached. Scores
were recorded to the nearest tenth of a second.
Note on Data Collection
In order to ensure accurate measurement, two trained observers collected data during each
trial of tail pinch and open field testing, with the dependent variables divided between them.
During a tail pinch trial for example, one observer recorded oral stereotopy with food and
grooming, while the other recorded oral stereotopy without food and vocalizations. A similar
division of dependent variables was adopted for the open field condition. Unless otherwise noted
above, duration measurements (e.g., oral stereotopy with food) were recorded to the nearest
hundredth of a second. All measurements of weight (e.g., eating) were recorded to the nearest
hundredth of a gram.
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Histology
Animals that received stereotaxic surgery were euthanized following the rotarod
procedure and a histological analysis was performed to insure proper placement of cannulae for
ICV injections. Animals were euthanized with an overdose of ether and 5 µl of ink was injected
bilaterally using the guide cannulae. Following ink injection, animals were perfused transcardially
with 30 cc of physiologic saline followed by 30 cc of phosphate-buffered formalin. The brains
were extracted and stored in formalin for at least 24 hours. Eighty µm sections were taken
through the site of implantation using a freezing microtome. Sections were examined under the
microscope and visual confirmation of bilateral implantation was made. Only data for those
animals with correct implantation were considered in analysis.

39

RESULTS
Statistical Procedures
Tail pinch and open field data were analyzed using Multivariate Analysis of Variance
(MANOVA), with two exceptions: flat body posture and rotarod. Due to the nominal nature
(i.e., presence or absence) of the flat body posture data, they could not be included in multivariate
analysis and were analyzed separately using χ2 analysis. Because all animals did not complete
rotarod testing due to attrition or failure to satisfy the 30-second rotarod training criterion,
rotarod data were analyzed separately using univariate analysis of variance. Significant MANOVA
result for each experiment was followed up with univariate analysis of variance for each
dependent variable included in the design, and tests of Least Significant Differences were
conducted on each significant univariate test in order to describe the between-group differences
observed. Alpha was set a priori at .05 for all tests. Significant findings are reported by
experiment below (refer to the Appendix for non-significant data).
General Notes
For ease of reading, drug doses from this point forward are referred to as low, middle and
high where appropriate. Doses are labeled in each figure, however Table 2 below is provided as
an additional reference.
Table 2: Doses designated as ‘low,’ ‘middle,’ or ‘high’ for each experiment.
Experiment 1
Experiment 4
Experiment 2
Experiment 5
DOI (mg/kg)
KET (mg/kg)
DOI (µg)
DOI (mg/kg)
KET (mg/kg)
Low = 0.1
Low = 0.5
Low = 20
Low = 0.5
5.0
Middle = 0.5
Middle = 2.5
Middle = 100
High = 1.0
High = 5.0
High = 200
High = 1.0
In no experiment did administration of either drug result in significant motor impairment
as measured by rotarod performance (see the Appendix).
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Experiments 1 & 4: Peripheral DOI and KET
Data for Experiments 1 and 4 were combined into one multivariate analysis for
conservation of alpha error. Overall MANOVA was significant [F (78, 390) = 2.705, p < .001].
Significant differences were found between drug groups for eight of the thirteen variables
included in the analysis: oral stereotopy with food [F (6, 72) = 4.169, p = .001] and without food
[F (6, 72) = 5.479, p < .001], vocalizations [F (6, 72) = 2.569, p = .026], gnawing [F (6, 72) =
2.415, p = .035], rearing [F (6, 72) = 13.59, p < .001], headshakes [F (6, 72) = 10.177, p < .001],
body shakes [F (6, 72) = 6.949, p < .001], freezing [F (6, 72) = 2.587, p < .025]. The groups
differed on flat body posture as well [χ2 (3) = 34.29, p < .001].
Oral stereotopy with food is depicted below in Figure 4. The group that received the high
dose of DOI exhibited significantly less oral stereotopy with food than the group that received
saline (p = .037) While neither group that received the low or middle dose of DOI behaved
differently from the saline control group, a dose-related trend towards behavioral reduction is
evident.
Unlike the dose-related stepwise reduction in behavior observed in Experiment 1 with
DOI administration, a U-shaped increase in oral behavior directed at food emerged in animals
administered KET in Experiment 4. Specifically, the group that received the low dose of KET
performed significantly more oral stereotopy with food than the saline control group (p = .023),
the groups that received the low (p = .037), the middle (p <.001), or the high (p < .001) doses of
DOI, as well as the middle dose (p = .028) of KET. The group that was administered the high
dose of KET also spent significantly more time engaged in oral behavior directed at food than the
groups administered the middle (p = .008) or high (p = .002) doses of DOI.

41

140
120

Time (seconds)

100
80
60
40
20
0
Saline

DOI 0.1

DOI 0.5

DOI 1.0

KET 0.5

KET 2.5

KET 5.0

Single Injection Groups (mg/kg)

Figure 4: Oral Stereotopy with Food after Peripheral administration of Saline, DOI, or KET
Oral stereotopy without food is shown in Figure 5 below. The groups that received either
the middle or high doses of DOI performed significantly less oral stereotopy directed at the testing
cage than the saline control group with probability values of (p = .004) and (p = .006)
respectively.
The group that was administered the low dose of DOI behaved no differently than the
saline control group, and spent a significantly longer amount of time engaged in oral stereotopy
without food than the groups receiving any of the three doses of KET (low (p = .037), middle (p
= .001) and high (p < .001)), and the other two doses of DOI as well (middle (p < .001) and high
(p = .001)). All three groups that received KET (low (p = .001), middle (p = .007) and high (p =
.004) doses) performed significantly less oral stereotopy without food than did the saline control
group.
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Figure 5: Oral Sterotopy without Food after Administration of Saline, DOI, or KET

Figure 6 below shows the data for Vocalizations. Despite a dose-related trend towards a
reduction in the number of vocalizations emitted by animals that were administered DOI, none of
the groups receiving DOI differed significantly from the saline control group on vocalizations.
The group that was administered the low dose of DOI vocalized significantly more than the
middle (p = .032) and high (p = .023) doses of DOI, as well as the low dose of KET (p = .037).
The group receiving the middle dose of KET emitted significantly more vocalizations than the
groups receiving saline (p = .045), the middle (p = .005) and high (p = .003) doses of DOI, as
well as the low dose of KET (p = .012).
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Figure 6: Vocalizations after Administration of Saline, DOI, or KET

Gnawing data is depicted in Figure 7 below. None of the groups that were administered
drug (DOI or KET) behaved significantly differently from the saline control group on the amount
of food gnawed during tail pinch. There was however, a non-significant trend towards behavioral
reduction in the amount of food gnawed for animals that were injected with DOI.
The group that received the low dose of DOI gnawed significantly more food than those
that received the middle (p = .029) or high (p = .026) doses of DOI. The animals that were
administered the low dose of KET performed significantly more gnawing than the groups that
were injected with either the middle (p = .006) or high (p = .005) doses of DOI, and the middle (p
= .034) dose of KET as well.
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Figure 7: Gnawing after Administration of Saline, DOI, or KET
The data for Rearing is presented below in Figure 8. For this variable, all groups that were
administered drug (DOI or KET) performed significantly fewer instances of rearing behavior in
the open field condition than did the saline control group. Specifically, the groups receiving the
low (p < .001), middle (p < .001), and high (p < .001) doses of DOI exhibited a dose-dependent
reduction in rearing compared to the control group, and the group that received the high dose of
DOI performed significantly less rearing behavior than the low dose of DOI (p = .042).
While the animals that were administered the low (p = .002), middle (p = .009) and high (p
= .004) doses of KET all performed significantly less rearing behavior than the control group,
they performed significantly more rearing than the middle and high doses of DOI, with all
probability values at or below p = .001. The group that received the middle dose of KET also
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performed significantly more rearing compared to the group that received the low dose of DOI (p
= .050).
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Figure 8: Rearing after Administration of Saline, DOI, or KET
The following two graphs depict Headshakes (Figure 9) and Wet dog shakes (Figure 10).
The groups receiving either the middle or high dose of DOI displayed a significantly higher
number of headshakes in the open field than the saline control, all three groups that received KET,
and the group that was administered the low dose of DOI (all comparisons p <.001).
Similar to the headshake variable, the group that received the middle dose of DOI
displayed significantly more wet dog shakes in the open field than all other groups, with p < .001
for all comparisons.
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Figure 9: Headshakes after Administration of Saline, DOI, or KET
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Figure 10: Wet Dog Shakes after Administration of Saline, DOI, or KET
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Figure 11 below shows the data for Freezing. No group that was administered DOI
behaved differently from the saline control group on the amount of time spent freezing in the open
field. In fact, only one group of animals displayed a significant change in behavior on this variable.
The group that was administered the high dose of KET spent a significantly longer amount of time
freezing than the saline control group (p = .004), the group that received the low dose of DOI (p
= .005), and the groups that received either the middle (p = .004) or low (p = .009) doses of
KET.

25

Time (seconds)

20

15

10

5

0
Saline

DOI 0.1

DOI 0.5

DOI 1.0

KET 0.5

KET 2.5

KET 5.0

Single Injection Groups (mg/kg)
Figure 11: Freezing after Administration of Saline, DOI, or KET
Flat body posture data is depicted below in Figure 12. Flat body posture occurred in a
significantly higher proportion of animals that received DOI than in those that received saline,

48

with 83.3% of animals in both the middle and high dose groups exhibiting flat body posture and
0% of animals receiving saline, the low dose of DOI, or any dose of KET exhibiting flat body
posture.
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Figure 12: Flat Body Posture after Peripheral Administration of Saline, DOI or KET

Experiment 2: Central DOI
MANOVA revealed a significant effect of centrally administered DOI [F (39,123) = 1.999;
p = .003]. In the tail pinch condition, only vocalizations were different between drug groups [F
(3,50) = 3.00, p = .04], and in the open field condition, headshakes [F (3,50 = 15.94, p <.001] and
wet dog shakes [F (3,50) = 3.20, p = .03] were different. Flat body posture was significantly
increased by DOI [χ2 (3) = 13.35, p = .004].
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Figure 13 shows the average number of Vocalizations. Compared to the saline control,
vocalizations were reduced by centrally administered DOI at the low (p = .01) and high (p = .02)
doses.
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Figure 13: Vocalizations Following Centrally Administered DOI

Headshakes (Figure 14) and Wet dog shakes (Figure 15) for Experiment 2 are shown
below.
Headshakes were significantly increased by both the middle (p = .001) and high doses (p <
.001) of DOI in comparison to the control group. This effect was dose-dependent, with the high
dose significantly increasing headshakes compared to the low (p < .001) and middle (p = .004)
doses of DOI. Wet dog shakes were increased significantly only by the high dose of DOI (p =
.008) compared to the saline control group.
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Figure 14: Headshakes Following Centrally Administered DOI
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Figure 15: Wet Dog Shakes Following Central Administration of DOI
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Flat body posture is shown below in Figure16. No animal receiving saline injection
displayed flattened body posture, but 8%, 50%, and 42% of animals in the groups receiving low,
middle, and high (respectively) doses of DOI did display the posture.
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Figure 16: Flat Body Posture Following Central Administration of DOI
Experiment 3: Central + Peripheral DOI
MANOVA for this experiment was significant [F (12,10) = 3.207, p = .037]. In the tail
pinch condition, behavioral reduction in three variables was observed following administration of
DOI, and in the open field two behaviors were significantly increased by DOI.
Oral stereotopy with food is depicted in Figure 17, below. The amount of time animals
engaged in oral stereotopy directed at food during the tail pinch test was significantly decreased in
animals that were administered DOI [F (1,21) = 10.47, p = .004].
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Figure 17: Oral Stereotopy with Food after Central + Peripheral Injections of Saline or DOI
Eating (Figure 18) and Gnawing (Figure 19) are shown below, followed by Headshakes
(Figure 20) and Wet dog shakes (Figure 21).
Administration of DOI peripherally and centrally resulted in a significantly reduced amount
of food material being eaten by animals [F (1,21) = 6.53, p = .018]. The amount of food gnawed
was significantly reduced following central plus peripheral injection of DOI [F (1,21) = 4.91, p =
.038].
The number of headshakes in the open field was significantly increased by DOI [F (1,21) =
18.72, p < .001]. Wet dog shakes were also significantly increased in animals injected with DOI
compared to the saline control [F (1,21) = 6.26, p = .021].
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Figure 18: Eating after Central + Peripheral Injections of Saline or DOI
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Figure 19: Gnawing after Central + Peripheral Injections of Saline or DOI
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Figure 20: Headshakes after Central + Peripheral Injections of Saline or DOI
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Figure 21: Wet dog shakes after Central + Peripheral Injections of Saline or DOI
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Experiment 5: Peripheral DOI + Peripheral KET
Overall comparison of the behavior of animals that received one of six different
combinations of double peripheral injections: saline, a low dose of DOI + saline, a high dose of
DOI + saline, KET + saline, low dose of DOI + KET, or high dose of DOI + KET, resulted in a
significant MANOVA [F (65, 410) = 2.912, p = <.001]. Specifically, significant differences were
observed between drug groups in three behavioral measures in the tail pinch condition: oral
stereotopy with food [F (5, 90) = 5.593, p <.001], vocalizations [F (5, 90) = 4.508, p = .001], and
eating [F(5, 90) = 3.439, p = .007]. The difference in the amount of time animals spent grooming
also approached significance [F (5, 90) = 2.213, p = .06] in the tail pinch condition. In the open
field, the amount of rearing [F (5, 90) = 12.37, p< .001], headshakes [F (5, 90) = 16.983. p<
.001], and flattened body posture [χ2 (5) = 62.3, p < .001] displayed by animals in the different
drug groups was significantly altered in the open field condition.
Oral stereotopy with food is depicted below in Figure 22. Post hoc findings were in the
predicted direction, with behavior evoked by tail pinch stress being significantly decreased by DOI
compared to the saline control group (the high dose (p = .003) or the low dose (p = .021) of DOI
+ saline). This DOI effect was reversed by KET administration. Animals that received either KET
+ saline or KET + DOI (either dose) did not differ from the saline control group in the amount of
time engaged in oral behavior directed at food. The group that received the low dose of DOI +
KET engaged in significantly more oral stereotopy with food than the group that received the low
dose + saline (p = .001). Similarly, the group administered the high dose of DOI + KET spent
significantly more time with food than the group that was given the high dose of DOI + saline (p
= .043).
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Figure 22: Oral Stereotopy with Food after Double Peripheral Injection.
The animals administered the low dose of DOI + saline spent less time engaged with food
than those that received KET + saline (p = .002). The group that received the high dose of DOI +
saline performed significantly less oral stereotopy with food than both the KET + saline group and
the group administered the low dose of DOI + KET (both comparisons p < .001).
Eating is shown below in Figure 23. The groups that received DOI + saline ate
significantly less during the tail pinch test than the saline control group (high (p = .001) and low
(p = .007) doses). While the animals that were administered the low dose of DOI + KET did not
eat significantly more than did the animals that received the low dose of DOI + saline, they (unlike
the low dose of DOI + saline) also did not differ from the saline control, indirectly indicating a
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reversal of the DOI effect. The group that was administered the high dose of DOI + KET ate less
(p = .027) than the saline control group, suggesting that the ability of KET to reverse the effect of
DOI on eating during tail pinch stress is dose-related.
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Figure 20: Eating after Double Peripheral Injection.
The group given the low dose of DOI + saline ate significantly less than the group given
KET + saline (p = .034). The group administered the high dose of DOI + saline ate significantly
less than both the low dose of DOI + KET (p= .022) and the KET + saline (p = .009) groups.
Figure 24 below shows data for Vocalizations. The two groups that received the low
dose of DOI vocalized more than every other group with only one exception: low dose of DOI +
KET compared to the high dose of DOI + KET. Specifically, the groups given the low dose of
DOI + saline and low dose of DOI + KET vocalized more than the saline control (p = .002 and p
= .023, respectively), the group administered the high dose of DOI + saline (p < .001 and p =
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.003), and the group that was administered KET + saline (p = .002 and p = .024). The group that
received the low dose of DOI + saline also vocalized significantly more than the group that
received the high dose of DOI + KET (p = .049). A near significant increase in vocalizations was
observed for the group that received the high dose of DOI + KET compared to the high dose of
DOI + saline (p = .065)
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Figure 24: Vocalizations after Double Peripheral Injection.
Rearing is shown below in Figure 25. The groups that received either the high (p < .001)
or the low (p = .001) dose of DOI + saline performed significantly less rearing than the saline
control group in the open field. All three KET groups performed significantly more rearing than
the groups that received the high or the low doses of DOI + saline (all comparisons at or below p
= .001).
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Figure 25: Rearing after Double Peripheral Injection.

Head Shakes (Figure 26) and Flat body posture (Figure 27) are shown below. The groups
that received either the high or the low dose of DOI + saline performed significantly more
headshakes than the saline control and all three groups that were administered KET, with all
differences at or below p = .001. Flat body posture was observed in a significantly higher
proportion of animals that received DOI than those that received saline or KET, with 100% of
animals in the group that received the high dose of DOI + saline and 50% in the group that
received the low dose of DOI + saline exhibiting flattened body posture. Only 6.25% of animals
that received either dose of DOI + KET or saline, and 0% of animals that received KET + saline
exhibited the flattened posture.
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Figure 26: Headshakes after Double Peripheral Injection.
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Figure 27: Flat Body Posture after Double Peripheral Injection
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DISCUSSION
In general, the results of the five experiments supported the original hypotheses, showing
a decrease in behavioral responding to stress with administration of the 5-HT2A/C agonist DOI and
a reversal of this decrease with administration of the 5-HT2A/C antagonist KET (see Table 3
below). Administration of DOI resulted in significantly decreased behavioral responding to tail
pinch stress in all five experiments, regardless of route of administration. Peripheral injection of
DOI resulted in the maximal behavioral change (i.e., the highest number of dependent variables
with significant behavioral reductions) in the tail pinch condition. Central + peripheral injection
also resulted in significant reduction in several behaviors, but central injection alone reduced
responding in only one behavior in the tail pinch test. Behavioral responding to tail pinch stress
following peripheral injection of KET was increased compared to animals that were administered
DOI and in some cases increased compared to the saline control. There was only one case in
which behavior evoked by tail pinch stress was significantly decreased following administration of
KET compared to saline. As hypothesized, concomitant peripheral administration of KET and
DOI resulted in a reversal of the decrease in stress-evoked behaviors seen with administration of
DOI alone that is, the return of behavioral responding to tail pinch stress significantly higher than
the DOI groups and/or to a level equal to the saline control group.
DOI
The pattern of behaviors observed in the tail pinch test suggests that activation of 5-HT2
systems centrally and/or peripherally results in an anxiolytic effect. This suggestion is similar to
other findings in the literature. Compared to the saline control group, peripheral injection of DOI
in both the single and double injection conditions (i.e., Experiments 1 & 5) resulted in significant
dose-related reductions in oral behavior directed at food, the amount of food gnawed, as well as
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Table 3: Summary of significant findings for Experiments 1-5.

Dependent
Variables
Tail Pinch

Exp1
Peripheral
DOI
DOI decreased

DOI decreased
compared to
saline
DOI decreased
compared to
saline
DOI decreased
compared to
saline

OS with food compared to
saline

Eating
Gnawing
OS without
food

Exp 3
Central +
Peripheral
DOI

Exp 2
Central DOI

DOI decreased
compared to
saline
DOI decreased
compared to
saline

Exp 4
Peripheral
KET
KET increased
compared to
saline

Exp 5
Peripheral
KET + DOI
KET reversed
DOI effect
KET reversed
DOI effect

KET
decreased*
compared to
saline

Grooming
DOI decreased

Vocalizations compared to
saline

DOI decreased
compared to
saline

KET increased
compared to
saline

KET reversed
DOI effect

KET
decreased
compared to
saline

KET reversed
DOI effect

Fecal boli
Open Field
Rearing

DOI
decreased*
compared to
saline

Line crossing
KET increased
compared to
saline

Freezing
Headshakes
Wet dog
shakes
Flat body
posture

DOI increased
compared to
saline
DOI increased
compared to
saline
DOI increased
compared to
saline

DOI increased
compared to
saline
DOI increased
compared to
saline
DOI increased
compared to
saline

DOI increased
compared to
saline
DOI increased
compared to
saline

KET reversed
DOI effect

KET reversed
DOI effect

* indicates a significant finding in the unexpected (opposite of hypothesized) direction.
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oral behavior not directed at food or self (cage licking, vacuous chewing, teeth chattering), and
vocalizations in animals exposed to tail pinch stress. However, animals that were administered
DOI centrally behaved differently from the saline group on just one variable: vocalizations.
Simultaneous administration of central and peripheral injections of DOI resulted in significant
behavioral reduction similar to those seen with peripheral injection alone – reduction was
observed in oral stereotopy with food (due to both eating and gnawing), though the reduction in
non-food directed oral behavior and vocalization seen in the peripherally injected animals was
absent from the central + peripheral results. In no instance was behavior produced following any
of the three modes of administration (peripheral, central, or central + peripheral) that indicated
increased reaction to tail pinch stress. These findings are similar to previous reports, indicating
that administration of DOI leads to reduced behavioral responding to stress, indicative of an
anxiolytic response. Several studies found that DOI decreased escape behavior (Nic
Dhonnchadha, Hascoet, Jolliet, & Bourin, 2003; Nic Dhonnchadha, Bourin, & Hascoet, 2003; de
Paula Soares & Zangrossi, Jr., 2004) and increased exploratory behaviors (Peng et al., 2004) in
the elevated plus maze. Others have reported similar results with a foot shock stressor, where
both adult and young rats exhibited reduced ultrasonic vocalization following administration of
DOI (De Vry, Benz, Schreiber, & Traber, 1993; Sanchez, 1993; Schreiber, Melon, & De Vry,
1998; Winslow & Insel, 1991). Njung’e and Handley (1991) found that DOI reduced marble
burying, a behavioral measure of anxiety, and Nic Dhonnchadha et al. (2003b) reported DOI to be
anxiolytic in the four plates test in mice.
The possibility that the reductions in responding observed in the current experiments are
due to a nonspecific motor impairment preventing a response, rather than a decrease due to an
actual anxiolytic action of DOI, is made less likely by the fact that administration of DOI did not
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significantly affect grooming (in the tail pinch test), locomotion (as measured by line crosses in the
open field test), or rotarod performance (test of motor function exclusively) at any of the doses or
modes of administration tested. This finding confirms previous work (Raghavendra & Kulkarni,
2000b; Redrobe et al., 1997). However, increases (Darmani, Shaddy, & Gerdes, 1996; Granoff &
Ashby, Jr., 1998) and decreases (Kaur & Ahlenius, 2000; Krebs-Thomson & Geyer, 1996) in
locomotion following administration of DOI have also been reported.
The effect of DOI on stress responding to the open field stressor was consistent across all
three modes of administration, with one exception: in both Experiments 1 and 5, peripherally
injected DOI produced a decrease in rearing compared to the saline control, while neither of the
other two modes of administration produced this effect. This behavioral decrease, indicative of an
anxiogenic action of DOI, has been reported previously (Kaur et al., 2000), but in this case
appears to be due to differences between the saline control groups rather than differences in
behavioral responding to DOI. Rearing was substantially increased in the two peripheral saline
control conditions compared to central and central + peripheral saline injections (Figure 28
below).
Rearing observed following peripheral administration of any dose of DOI was comparable
to that observed after both central and central + peripheral injections. Conclusions about whether
these differences in responding between the control groups are due to random variation or to
differences in the injection protocols would require further investigation.
The animals that received the middle or high doses of peripherally injected DOI, the high
dose of centrally injected DOI, and the central + peripheral injection of DOI consistently displayed
significantly more head and wet dog shakes than the saline control group. Additionally, flat body
posture was observed following peripheral and central injection of DOI. These behaviors are
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known to be mediated by 5-HT2 receptors (Heslop & Curzon, 1999; Takao et al., 1995),
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Figure 28: Difference in Rearing in Control Animals by Injection Group

indicating that the drug was still in effect at the time of the open field test (Benjamin, Knapp, &
Pohorecky, 1993).While head and body shakes are usually thought of as a pharmacological effect,
exposure to stress has been reported to influence the number of shakes elicited by DOI, with both
increases (Brotto, Gorzalka, & Hanson, 1998; Chaouloff, Baudrie, & Coupry, 1994; Takao et al.,
1995) and decreases (Izumi et al., 2002; Pericic, 2003; Yamada, Nankai, & Toru, 1993; Yamada,
Watanabe, Nankai, & Toru, 1995) in shakes reported when animals were exposed to metabolic,
restraint, swim, foot shock or tail pinch stressors prior to administration of DOI. These reports
suggest the possibility that the number of head and body shakes observed in the open field could
have been influenced by the animals’ prior exposure to the tail pinch stressor. The lack of any
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such effect on the saline control group, however, argues against this possible influence. Others
(Van Oekelen, Megens, Meert, Luyten, & Leysen, 2003) have reported increased headshakes
following cranial surgery, purportedly as a result of damage to the blood brain barrier. This
finding was not replicated in the control conditions for the current Experiment 2 or 3, in which
cranial surgery was performed.
The lack of significant change compared to the saline control in the number of line crosses
and freezing following any injection of DOI suggests that, in contrast to the tail pinch stressor,
stimulating 5-HT2A/C receptors has little effect on behavioral responding to an open field stressor.
Ketanserin
Increased behavioral responding compared to saline-injected animals was seen in two
variables in the tail pinch condition following KET injection, vocalizations and oral stereotopy
with food, but this increase was not linearly related to dose. Increasing the dose of KET resulted
in a U-shaped dose-response (i.e., middle dose resulted in biggest reduction in behavior) in the
case of oral stereotopy with food, and an inverted U-shaped dose response (i.e., middle dose
resulted in biggest increase in behavior) for the number of vocalizations emitted. This is in
contrast to the findings following administration of DOI, where the level of responding evoked by
tail pinch stress on these two dependent measures was consistently reduced as a function of
increasing dose (i.e., highest dose resulted in the least amount of responding). In the open field,
the time spent engaged in freezing behavior was significantly increased compared to saline control
for animals that received the high dose of KET. While this effect was not replicated at a
statistically significant level in the open field test for Experiment 5 (in which one group of animals
received the high dose of KET + an injection of saline), those animals that received KET + saline
did spend more time freezing than those that received saline (an approximately five-fold increase;
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see Table 7 in the Appendix). Behavioral increases such as these following the administration of
KET have been reported previously with exposure to stressors such as the light/dark paradigm
and elevated plus maze (Zangrossi & Graeff, 1994; Nic Dhonnchadha et al., 2003).
Administration of KET also resulted in decreased behavioral responding compared to the
saline control in the tail pinch condition for oral stereotopy without food (all doses), as well as
significantly decreasing rearing behavior in the open field (all doses). Like the DOI results
described above, rotarod performance was unaffected, suggesting that these reductions in
behavioral responding to stress are not attributable to a general motor effect of KET. A few
previous reports have indicated that administration of KET can result in an anxiolytic effect on
behavioral responding in animals exposed to stress. For example, published reports indicate that
administration of KET reduced freezing behavior during conditioned fear stress in rats (IshidaTokuda et al., 1996), increased the threshold of aversive brain stimulation (in the periaqueductal
gray) for eliciting escape behavior (Jenck, Broekkamp, & Van Delft, 1989), and reversed the
hypophagic effect of restraint stress when injected into the periventricular nucleus of the
hypothalamus (Grignaschi et al., 1993). However, no such reports have been published for tail
pinch or open field stressors, and other studies have only found anxiolytic effects with KET under
very particular circumstances. For example, Diaz-Veliz et al. (1997) found increased behavior
consistent with an anxiolytic action of KET in the elevated plus maze (increased entries and
exploration of open arms), but only in diestrous female rats; the effect was absent in males,
ovariatectomized females, and females in other stages of the estrous cycle. Da Rocha, Jr., Puech,
and Thiebot (1997) reported a decrease in immobilization following swim stress in mice, but this
effect was found only following the administration of an atypically large (32 mg/kg) dose of KET.
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No differences were found on eight of the 13 variables measured in both the tail pinch and
open field tests. This absence of effect of KET on behavior has also been previously reported
following exposure to other stressors: e.g., it had no effect on behavior evoked by the elevated Tmaze (de Paula Soares & Zangrossi, 2004), the light/dark paradigm, social interaction (Costall &
Naylor, 1995), or conditioned fear stress (Inoue, Tsuchiya, & Koyama, 1996).
Variations in Reported findings with 5-HT2A/C Agonists and Antagonists
It is well known that stimulation or blockade of 5-HT2A/C receptors may lead to opposite
effects on behavior depending upon the type of stressor employed (Millan, 2003). However, as
reviewed above, administration of agents that manipulate activity at 5-HT2A/C receptors has also
resulted in variable findings in studies employing the same stressor. While more research is clearly
needed to explain these differences, variations in methodology may explain at least some of the
reported differences. The use of different doses of DOI or KET is one such variation – doses
range widely from report to report and, as described above in the 5-HT as anxiolytic section, at
least one study has found decreased behavioral responsiveness to stress with low doses of DOI
and increased behavioral responsiveness to stress following administration of high doses of DOI
(Onaivi et al., 1995). Varying the route of administration has also been shown to have different
effects on behavior; for example, Larson and Kondzielski (1982) found that 5-HT injected
peripherally reduces gnawing behavior in response to a tail pinch stressor, but produces gnawing
when injected intrathecally. Another possible methodological explanation for the inconsistent
results between reports could be the length or chronicity of the stressor to which the animals were
exposed. One example where variation in length of exposure to a stressor is common is restraint
stress. Studies of 5-HT activity employing restraint stress have reported exposure to the stressor
varying from five minutes (e.g., Uphouse et al., 2003; Saphier et al., 1995) to up to two hours
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(e.g., Whitton, Sarna, Datla, & Curzon, 1991; Kennett, Chaouloff, Marcou, & Curzon, 1986).
Conditioned fear stress requires, by definition, repeated exposure to the stressor – it is possible
that this repeated exposure causes some enduring physiological change that alters the drug effect
at the time of testing or that the number of exposures vary between studies, and that this variation
has some measurable impact on responding following drug administration. While there are
currently no reports of direct manipulations of stressor chronicity or length of single exposure
relating to 5-HT activity and behavioral responding to stress, the number of 5-HT2 receptors
increases following exposure to a chronic, but not an acute restraint stressor (Takao et al., 1995).
This provides indirect evidence of a possible mechanism by which differences in characteristics of
the stressor may result in contradictory findings.
In addition to the methodological differences suggested above, some property of the 5HT2A/C receptor itself may be responsible for these contradictory reports. For instance, variations
in responsiveness at different points in the circadian cycle could be responsible for the differences
observed in behavioral responding to stress. Studies employing the same stressor, route of
administration, and dose of DOI or KET, but reporting contradictory results, may have tested the
animals at different times of day. Nagayama and Lu (1996) conducted a between-group study in
which rats were injected peripherally with DOI at four-hour intervals throughout the day. Wet
dog shakes were observed at a significantly higher rate in the early morning (0400) than in the
afternoon (1600), an effect replicated with central injection of DOI as well. This behavioral
measure was made in the absence of a stressor; however, if baseline behavioral responding is
affected by circadian rhythm, it is possible that behaviors evoked by stressors could be affected by
the same rhythms. Unfortunately, many studies fail to report the time of day testing was
performed, making the possible influence of circadian cycles difficult to determine.
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DOI + Ketanserin
KET systematically reversed the behavioral reductions observed with administration of
DOI in the tail pinch condition and open field, as hypothesized. Significant blockade of the DOI
effect was observed in the measurement of oral stereotopy with food, eating, and vocalizations in
the tail pinch condition, as well as rearing, headshakes, and flat body posture in the open field.
These results provide strong evidence that the changes in behavioral responding observed
following injection of DOI are, in fact, due to activation of the 5-HT2A/C receptors.
While this is the first report describing the reversal by KET of the effect of DOI on
behaviors evoked by tail pinch and open field stressors, reversal of decreased stress responding
has been reported previously in different stress paradigms following injection of DOI as well as
other 5-HT2 agonists. Schreiber et al (1998) reported that KET blocked the anxiolytic effects of
DOI in the ultrasonic vocalization test. KET reversed the anxiolytic effect of aniracetam in the
social interaction test with mice and reversed headshakes induced by benzodiazepine injection
(Nakamura & Kurasawa, 2001; Tadano et al., 2001). De Paula Soares and Zangrossi (2004)
found that decreased escape behaviors in the elevated T-maze were reversed by KET injection,
and Graeff, Brandao, Audi, and Schutz (1986) reported that the anti-aversive effect of 5-HT
injection in the dorsal periaqueductal gray was blocked by KET. Like the findings from
Experiment 5, these reports also seem to suggest that administration of KET consistently reverses
the behavioral decreases caused by 5-HT2 agonists administered in the presence of a stressor.
However, when injected alone in Experiment 4, KET did significantly increase behavioral
responding on two of these measures in the tail pinch test: oral stereotopy with food and
vocalizations. These observed increases create the possibility that KET could be acting indirectly,
through some competing process, to elevate behavioral responding rather than directly blocking
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or reversing the DOI effect. While possible, this scenario seems unlikely considering the striking,
complete reversal of the pharmacological effect of DOI on headshakes and flat body posture in
the open field, behaviors thought to result exclusively from activity of the 5-HT2A/C receptors.
Central vs. Peripheral Site of Action
The question of whether the observed behavioral changes resulted from manipulation of
central or peripheral 5-HT2A/C receptors is not easily determined from the results of this series of
experiments. The consistent effect of DOI on head and wet dog shakes, behaviors known to be
centrally mediated, following central and central + peripheral modes of administration, argues for
a central site of action, and has been suggested by others (e.g., Dey, 1994; Nankai, Yamada,
Muneoka, & Toru, 1995). On the other hand, the lack of effect of DOI following central injection
on four of the eight behavioral variables that were significantly affected by peripheral injection
would suggest a peripheral site of action. It is unlikely that the failure of centrally administered
DOI to significantly affect these oral behaviors in the tail pinch condition was due to an
insufficient concentration of DOI, as the 200 µg dose employed represents the maximum
solubility of the drug in water (10 µg/µl). It is notable, however, that while not significantly
reduced by central DOI injections in the tail pinch condition, the data suggested a dose-related
trend toward reduction in the amount of time animals engaged in oral behavior directed at food,
the amount of food gnawed, and oral behavior not directed at food or self (see Table 5 in the
Appendix). Additionally, the low peripheral dose and the high central dose, neither of which
produced an effect that was significantly different from saline when injected alone, did produce
significant reductions in the time animals engaged with food, the amount eaten, and the amount
gnawed during tail pinch stress when combined. The fact that these reductions in behavior were
similar to those seen with the bigger peripheral doses of DOI suggests that the effect of DOI
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could be both centrally and peripherally mediated. This suggestion is also supported by the results
of Experiment 5, which showed reversal of the DOI effect by peripheral administration of KET.
Previous reports provide strong evidence that manipulation of central 5-HT activity is likely
following peripheral administration of 5-HT agents, including DOI specifically (e.g., Amer, Breu,
McDermott, Wurtman, & Maher, 2004; Chaouloff, 1993).
It has been reported that 5-HT ligands injected into specific brain sites (rather than the
lateral ventricles as in Experiment 2) result in a more pronounced effect on behavior (McCall &
Clement, 1994). As discussed above (sections 5-HT Involvement in Stress Responding: CNS
pathways, and 5-HT as anxiolytic), Graeff and colleagues have suggested that increased 5-HT
activity in the ascending dorsal raphe pathway innervating the periaqueductal gray, the tectum of
the midbrain, and the amygdala, inhibits panic reactions (Zangrossi, Jr. et al., 2001), and that this
effect is blocked by central administration of KET (Brandao, Lopez-Garcia, Graeff, & Roberts,
1991). The possibility that DOI or KET injected into these areas might alter behaviors evoked by
tail pinch and open field stress remains to be investigated.
Limitations
Power
The number of animals included in each group represents the final number of animals
included in analysis following histology. MANOVA requires more cases per cell than dependent
variables being measured in the design to be sufficiently powered (Tabachnick & Fidell, 2001).
Following this rule, more animals than dependent variables were entered into each drug group for
each individual experiment, however, due to attrition from improper ICV implantation, tail
damage, or infection of peripheral injection site, final n for the experiments was, in some cases,
lower.
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In order to evaluate the effect reduced n may have had on the analyses performed, several
steps were taken post hoc to investigate whether or not the design employed was sufficiently
powered to test the hypotheses. First, estimates of observed power for all univariate tests were
calculated. These values ranged from 0.448 to 1.00 for Experiments 1 & 4 (with four of the
dependent variables with observed power <.80), from .069 to 1.00 for Experiment 2 (with 11 of
the dependent variables with observed power <.80), from .051 to .985 for Experiment 3 (with ten
of the dependent variables with observed power <.80), and from 0.256 to 1.00 for Experiment 5
(with seven of the dependent variables with observed power <.80). Eighty percent power is
generally thought of as the cutoff for an acceptable level of power in statistical tests; that several
of the univariate tests in each experiment fell below 80% observed power indicates an insufficient
sample size.
Second, a commonly used table of sample sizes was consulted (Hinkle, Wiersma, & Jurs,
1998). This table allows for determination of sample size based on power, effect size, and number
of treatment levels. According to this table, 203 animals would be required for Experiments 1 and
4 (actual number of animals tested = 79), 92 for Experiment 2 (actual = 55), 34 for Experiment 3
(actual = 23), and 163 for Experiment 5 (actual = 96) to achieve 80% power to detect a midrange effect on behavior in these experiments.
Third, a trial and error method was employed to test what effect doubling the sample size
in each experiment would have had on the outcome. In Experiments 1, 4, and 5, doubling the
sample size resulted in every dependent variable measured gaining significance. Results from
Experiments 2 and 3, however, required a quadrupled sample size to approximate the results in
the other three experiments. Taken together, these findings indicate that the results of this
experiment are limited by reduced power due to insufficient sample size. However, the fact that
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several variables were found to be significantly different between the drug groups, most notably in
the least powered test (i.e., for Experiments 1 & 4), speaks indirectly to the strength of the effects
reported.
Conclusions
This is the first report of the influence on behaviors evoked by tail pinch or open field
stress of centrally and peripherally administered DOI, and the reversal of that influence by the 5HT2A/C antagonist ketanserin. Despite the limitation of low power, the results from this series of
experiments support the hypothesis that stimulating 5-HT2A/C receptors results in an anxiolytic
effect, reducing behaviors evoked by tail pinch stress (specifically oral behavior directed at food),
and that peripherally administered KET reverses these effects. While these findings also suggest
that DOI has little effect on behaviors elicited by the open field test in rats, the analysis of power
and hypothetical manipulation of sample size described above indicate that this lack of effect
could be due to insufficient sample size. While the question of whether this effect is centrally or
peripherally mediated is unresolved, current theory would predict a central site of action, with
brain areas that contain projections from the dorsal raphe, such as the periaqueductal gray, being
important to the control of 5-HT on behavioral responding to a tail pinch stressor.
Future Directions
Given the results of these experiments, there are three logical follow up studies that should
be conducted. First, replicating these experiments with a larger sample size will help clarify the
full impact of DOI on behavioral responding during exposure to the tail pinch and open field
stressors, and the ability of KET to reverse that effect. Second, to help determine whether this is a
centrally or peripherally mediated effect, a central manipulation in which DOI is administered
peripherally and KET is administered centrally should be conducted. If the results from this
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second study were to argue for a central site of action, a third study in which measurement of
behavioral responding to stress following administration of DOI to specific brain areas (e.g.,
periaqueductal gray and/or amygdala) would be appropriate. The data yielded from such an
investigation would determine whether the results from the peripheral studies performed in the
current report can be replicated with site-specific central injections, as opposed to the ICV central
injections employed in Experiment 2. Building on the knowledge established in the current report,
these suggested manipulations would help further elucidate the role of the 5-HT2A/C receptors in
behavioral responding to stress.

76

REFERENCES
Abi-Saab, W. M., Bubser, M., Roth, R. H., & Deutch, A. Y. (1999). 5-HT2 receptor
regulation of extracellular GABA levels in the prefrontal cortex. Neuropsychopharmacology, 20,
92-96.
Adell, A., Casanovas, J. M., & Artigas, F. (1997). Comparative study in the rat of the
actions of different types of stress on the release of 5-HT in raphe nuclei and forebrain areas.
Neuropharmacology, 36, 735-741.
Alhaider, A. A. (1991). Antinociceptive effect of ketanserin in mice: involvement of
supraspinal 5-HT2 receptors in nociceptive transmission. Brain Research, 543, 335-340.
Amat, J., Matus-Amat, P., Watkins, L. R., & Maier, S. F. (1998). Escapable and
inescapable stress differentially alter extracellular levels of 5-HT in the basolateral amygdala of the
rat. Brain Research, 812, 113-120.
Amer, A., Breu, J., McDermott, J., Wurtman, R. J., & Maher, T. J. (2004). 5-Hydroxy-Ltryptophan suppresses food intake in food-deprived and stressed rats. Pharmacology
Biochemistry and Behavior, 77, 137-143.
Audi, E. A., de Oliveira, C. E., & Graeff, F. G. (1989). Serotonergic mediation of the
anxiolytic effect of intracerebrally injected propranolol measured in the elevated plus-maze.
Brazilian Journal of Medical and Biological Research, 22, 699-701.
Audi, E. A., de Oliveira, R. M., & Graeff, F. G. (1991). Microinjection of propranolol into
the dorsal periaqueductal gray causes an anxiolytic effect in the elevated plus-maze antagonized
by ritanserin. Psychopharmacology (Berl), 105, 553-557.
Awouters, F. (1985). The pharmacology of ketanserin, the first selective serotonin S2antagonist. Drug Development Research, 6, 263-300.
Barnes, N. M. & Sharp, T. (1999). A review of central 5-HT receptors and their function.
Neuropharmacology, 38, 1083-1152.
Bax, W. A., Heuven-Nolsen, D., Bos, E., Simoons, M. L., & Saxena, P. R. (1992). 5Hydroxytryptamine-induced contractions of the human isolated saphenous vein: involvement of 5HT2 and 5-HT1D-like receptors, and a comparison with grafted veins. Naunyn Schmiedebergs
Archives of Pharmacology, 345, 500-508.
Bell, A. A., Butz, B. L., & Alper, R. H. (1999). Cardiovascular responses produced by
microinjection of serotonin-receptor agonists into the paraventricular nucleus in conscious rats.
Journal of Cardiovascular Pharmacology, 33, 175-180.

77

Benjamin, D., Knapp, D. J., & Pohorecky, L. A. (1993). Ethanol prevents desensitization
of 5-HT2 receptor-mediated responses consequent to defeat in territorial aggression. Journal of
Studies on Alcohol (Suppl), 11, 180-184.
Blier, P., de Montigny, C., & Chaput, Y. (1987). Modifications of the serotonin system by
antidepressant treatments: implications for the therapeutic response in major depression. Journal
of Clinical Psychopharmacology, 7, 24S-35S.
Blokland, A., Lieben, C., & Deutz, N. E. (2002). Anxiogenic and depressive-like effects,
but no cognitive deficits, after repeated moderate tryptophan depletion in the rat. Journal of
Psychopharmacology, 16, 39-49.
Boess, F. G. & Martin, I. L. (1994). Molecular biology of 5-HT receptors.
Neuropharmacology, 33, 275-317.
Bonnin, A., Grimaldi, B., Fillion, M. P., & Fillion, G. (1999). Acute stress induces a
differential increase of 5-HT-moduline (LSAL) tissue content in various rat brain areas. Brain
Research, 825, 152-160.
Boutelle, M. G., Zetterstrom, T., Pei, Q., Svensson, L., & Fillenz, M. (1990). In vivo
neurochemical effects of tail pinch. Journal of Neuroscience Methods, 34, 151-157.
Brandao, M. L., Lopez-Garcia, J. A., Graeff, F. G., & Roberts, M. H. (1991).
Electrophysiological evidence for excitatory 5-HT2 and depressant 5-HT1A receptors on
neurones of the rat midbrain tectum. Brain Research, 556, 259-266.
Britton, D. R., Koob, G. F., Rivier, J., & Vale, W. (1982). Intraventricular corticotropinreleasing factor enhances behavioral effects of novelty. Life Sciences, 31, 363-367.
Brotto, L. A., Gorzalka, B. B., & Hanson, L. A. (1998). Effects of housing conditions and
5-HT2A activation on male rat sexual behavior. Physiology & Behavior, 63, 475-479.
Carli, M. & Samanin, R. (1988). Potential anxiolytic properties of 8-hydroxy-2-(di-npropylamino)tetralin, a selective serotonin 1A receptor agonist. Psychopharmacology (Berl), 94,
84-91.
Chaouloff, F. (1993). Physiopharmacological interactions between stress hormones and
central serotonergic systems. Brain Research Reviews, 18, 1-32.
Chaouloff, F., Baudrie, V., & Coupry, I. (1994). Effects of chlorisondamine and restraint
on cortical [3H]ketanserin binding, 5-HT2A receptor-mediated head shakes, and behaviours in
models of anxiety. Neuropharmacology, 33, 449-456.

78

Chaput, Y., Araneda, R. C., & Andrade, R. (1990). Pharmacological and functional
analysis of a novel serotonin receptor in the rat hippocampus. European Journal of
Pharmacology, 182, 441-456.
Chrousos, G. P. & Gold, P. W. (1992). The concepts of stress and stress system disorders.
Overview of physical and behavioral homeostasis. Journal of the American Medical Association,
267, 1244-1252.
Corda, M. G., Lecca, D., Piras, G., Di Chiara, G., & Giorgi, O. (1997). Biochemical
parameters of dopaminergic and GABAergic neurotransmission in the CNS of Roman highavoidance and Roman low-avoidance rats. Behavioral Genetics, 27, 527-536.
Costall, B. & Naylor, R. J. (1995). Behavioural interactions between 5hydroxytryptophan, neuroleptic agents and 5-HT receptor antagonists in modifying rodent
responding to aversive situations. British Journal of Pharmacology, 116, 2989-2999.
Curtis, A. L. & Valentino, R. J. (1994). Corticotropin-releasing factor neurotransmission
in locus coeruleus: a possible site of antidepressant action. Brain Research Bulletin, 35, 581-587.
Curzon, G. (1990). Serotonin and appetite. Annals of the New York Academy of the
Sciences, 600, 521-530.
Da Rocha, M. A., Jr., Puech, A. J., & Thiebot, M. H. (1997). Influence of anxiolytic drugs
on the effects of specific serotonin reuptake inhibitors in the forced swimming test in mice.
Journal of Psychopharmacology, 11, 211-218.
Darmani, N. A., Shaddy, J., & Gerdes, C. F. (1996). Differential ontogenesis of three
DOI-induced behaviors in mice. Physiology & Behavior, 60, 1495-1500.
de Paula Soares, V. & Zangrossi, H., Jr. (2004). Involvement of 5-HT1A and 5-HT2
receptors of the dorsal periaqueductal gray in the regulation of the defensive behaviors generated
by the elevated T-maze. Brain Research Bulletin, 64, 181-188.
De Vry, J., Benz, U., Schreiber, R., & Traber, J. (1993). Shock-induced ultrasonic
vocalization in young adult rats: a model for testing putative anti-anxiety drugs. European
Journal of Pharmacology, 249, 331-339.
De Vry, J. & Schreiber, R. (1997). The chronic mild stress depression model: future
developments from a drug discovery perspective. Psychopharmacology (Berl), 134, 349-350.
De Wied, D. & Croiset, G. (1991). Stress modulation of learning and memory processes.
Methods and Achievements in Experimental Pathology, 15, 167-199.

79

De, P. S., V & Zangrossi, H., Jr. (2004). Involvement of 5-HT1A and 5-HT2 receptors of
the dorsal periaqueductal gray in the regulation of the defensive behaviors generated by the
elevated T-maze. Brain Research Bulletin, 64, 181-188.
Deakin, J. F. (1991). Depression and 5HT. International Clinical Psychopharmacology, 6
Suppl 3, 23-28.
Derkach, V., Surprenant, A., & North, R. A. (1989). 5-HT3 receptors are membrane ion
channels. Nature, 339, 706-709.
Dey, S. (1994). Physical exercise as a novel antidepressant agent: possible role of
serotonin receptor subtypes. Physiology & Behavior, 55, 323-329.
Dhasmana, K. M., Zhu, Y. N., Cruz, S. L., & Villalon, C. M. (1993). Gastrointestinal
effects of 5-hydroxytryptamine and related drugs. Life Sciences, 53, 1651-1661.
Di Matteo, V., Di Giovanni, G., Di Mascio, M., & Esposito, E. (2000). Biochemical and
electrophysiological evidence that RO 60-0175 inhibits mesolimbic dopaminergic function
through serotonin(2C) receptors. Brain Research, 865, 85-90.
Dishman, R. K. (1997). Brain monoamines, exercise, and behavioral stress: animal models.
Medicine & Science in Sports and Exercise, 29, 63-74.
Dohms, J. E. & Metz, A. (1991). Stress--mechanisms of immunosuppression. Veterinary
Immunology and Immunopathology, 30, 89-109.
Dominguez, R., Cruz-Morales, S. E., Carvalho, M. C., Xavier, M., & Brandao, M. L.
(2003). Sex differences in serotonergic activity in dorsal and median raphe nucleus. Physiology &
Behavior, 80, 203-210.
Dormandy, J. A., Berent, A., & Downes, S. J. (1988). The use of the selective serotonin
S2 receptor antagonist Ketanserin in the treatment of Raynaud's phenomenon. European Journal
of Vascular Surgery, 2, 371-375.
Durand, M., Mormede, P., & Chaouloff, F. (2003). Wistar-Kyoto rats are sensitive to the
hypolocomotor and anxiogenic effects of mCPP. Behavioral Pharmacology, 14, 173-177.
Fricchione, G. L. & Stefano, G. B. (1994). The stress response and
autoimmunoregulation. Advances in Neuroimmunology, 4, 13-27.
Gaddum, J. H. & Picarelli, Z. P. (1957). Two kinds of tryptamine receptor. British
Journal of Pharmacology, 12, 323-328.
Gershon, M. D. (1991). Serotonin: its role and receptors in enteric neurotransmission.
Advances in Experimental Medicine and Biology, 294, 221-230.

80

Gibson, E. L., Barnfield, A. M., & Curzon, G. (1994). Evidence that mCPP-induced
anxiety in the plus-maze is mediated by postsynaptic 5-HT2C receptors but not by
sympathomimetic effects. Neuropharmacology, 33, 457-465.
Goldstein, J. M. (1999). Quetiapine fumarate (Seroquel): a new atypical antipsychotic.
Drugs Today (Barc.), 35, 193-210.
Gorzalka, B. B., Hanson, L. A., & Brotto, L. A. (1998). Chronic stress effects on sexual
behavior in male and female rats: mediation by 5-HT2A receptors. Pharmacology Biochemistry
and Behavior, 61, 405-412.
Gosnell, B. A., Morley, J. E., & Levine, A. S. (1983). A comparison of the effects of
corticotropin releasing factor and sauvagine on food intake. Pharmacology Biochemistry and
Behavior, 19, 771-775.
Goudreau, J. L., Wagner, E. J., Lookingland, K. J., & Moore, K. E. (1994). gammaAminobutyric acid receptor-mediated regulation of periventricular-hypophysial dopaminergic
neurons: possible role in mediating stress- and 5-hydroxytryptamine-induced decreases in
neuronal activity. Journal of Pharmacology and Experimental Therapies, 271, 1000-1006.
Graeff, F. G. (1993). Role of 5-HT in defensive behavior and anxiety. Reviews in the
Neurosciences, 4, 181-211.
Graeff, F. G. (1994). Neuroanatomy and neurotransmitter regulation of defensive
behaviors and related emotions in mammals. Brazilian Journal of Medical and Biological
Research, 27, 811-829.
Graeff, F. G. (1997). Serotonergic systems. Psychiatric Clinics of North America, 20,
723-739.
Graeff, F. G., Brandao, M. L., Audi, E. A., & Schutz, M. T. (1986). Modulation of the
brain aversive system by GABAergic and serotonergic mechanisms. Behavioral Brain Research,
22, 173-180.
Graeff, F. G., Silva, M., Del Ben, C. M., Zuardi, A. W., Hetem, L. A., & Guimaraes, F. S.
(2001). Comparison between two models of experimental anxiety in healthy volunteers and panic
disorder patients. Neuroscience and Biobehavioral Reviews, 25, 753-759.
Graeff, F. G., Viana, M. B., & Mora, P. O. (1997). Dual role of 5-HT in defense and
anxiety. Neuroscience and Biobehavioral Reviews, 21, 791-799.
Graeff, F. G., Zuardi, A. W., Giglio, J. S., Lima Filho, E. C., & Karniol, I. G. (1985).
Effect of metergoline on human anxiety. Psychopharmacology (Berl), 86, 334-338.

81

Granoff, M. I. & Ashby, C. R., Jr. (1998). The effect of the repeated administration of the
compound 3,4-methylenedioxymethamphetamine on the response of rats to the 5-HT2A,C
receptor agonist (+/-)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI).
Neuropsychobiology, 37, 36-40.
Grignaschi, G., Fanelli, E., Scagnol, I., & Samanin, R. (1999). Studies on the role of
serotonin receptor subtypes in the effect of sibutramine in various feeding paradigms in rats.
British Journal of Pharmacology, 127, 1190-1194.
Grignaschi, G., Mantelli, B., & Samanin, R. (1993). The hypophagic effect of restraint
stress in rats can be mediated by 5-HT2 receptors in the paraventricular nucleus of the
hypothalamus. Neuroscience Letters, 152, 103-106.
Grignaschi, G., Sironi, F., & Samanin, R. (1996). Stimulation of 5-HT2A receptors in the
paraventricular hypothalamus attenuates neuropeptide Y-induced hyperphagia through activation
of corticotropin releasing factor. Brain Research, 708, 173-176.
Grimaldi, B., Bonnin, A., Fillion, M. P., Prudhomme, N., & Fillion, G. (1999). 5Hydroxytryptamine-moduline: a novel endogenous peptide involved in the control of anxiety.
Neuroscience, 93, 1223-1225.
Hawkins, M. F., Baumeister, A. A., Larue, R. H., Fountain, L. T., Highsmith, R. W.,
Jeffries, S. K. et al. (1999). Central GABA activation and behaviors evoked by tail-pinch stress in
the rat. Physiology & Behavior, 67, 705-709.
Hawkins, M. F., Baumeister, A. A., Larue, R. H., Uzelac, S. M., Fountain, L. T., &
Hindelang, A. C. (2000). Manipulation of central GABAergic and dopaminergic systems alters
stress responding in the rat. Pharmacology Biochemistry and Behavior, 66, 667-670.
Heslop, K. E. & Curzon, G. (1999). Effect of reserpine on behavioural responses to
agonists at 5-HT1A, 5-HT1B, 5-HT2A, and 5-HT2C receptor subtypes. Neuropharmacology, 38,
883-891.
Hewitt, K. N., Lee, M. D., Dourish, C. T., & Clifton, P. G. (2002). Serotonin 2C receptor
agonists and the behavioural satiety sequence in mice. Pharmacology Biochemistry and Behavior,
71, 691-700.
Hinkle, D. E., Wiersma, W., & Jurs, S. G. (1998). Applied Statistics for the Behavioral
Sciences. (4th ed.) New York: Houghton Mifflin Company.
Hoebel, B. G. (1985). Brain neurotransmitters in food and drug reward. American
Journal of Clinical Nutrition, 42, 1133-1150.
Hoyer, D. (1988). Functional correlates of serotonin 5-HT1 recognition sites. Journal of
Receptor Research, 8, 59-81.

82

Hoyer, D., Clarke, D. E., Fozard, J. R., Hartig, P. R., Martin, G. R., Mylecharane, E. J. et
al. (1994). International Union of Pharmacology classification of receptors for 5hydroxytryptamine (Serotonin). Pharmacology Reviews, 46, 157-203.
Humphrey, P. P., Hartig, P., & Hoyer, D. (1993). A proposed new nomenclature for 5HT receptors. Trends in Pharmacological Science, 14, 233-236.
Inoue, T., Tsuchiya, K., & Koyama, T. (1994). Regional changes in dopamine and
serotonin activation with various intensity of physical and psychological stress in the rat brain.
Pharmacology Biochemistry and Behavior, 49, 911-920.
Inoue, T., Tsuchiya, K., & Koyama, T. (1996). Serotonergic activation reduces defensive
freezing in the conditioned fear paradigm. Pharmacology Biochemistry and Behavior, 53, 825831.
Ishida-Tokuda, K., Ohno, Y., Sakamoto, H., Ishibashi, T., Wakabayashi, J., Tojima, R. et
al. (1996). Evaluation of perospirone (SM-9018), a novel serotonin-2 and dopamine-2 receptor
antagonist, and other antipsychotics in the conditioned fear stress-induced freezing behavior
model in rats. Japanese Journal of Pharmacology, 72, 119-126.
Izumi, T., Suzuki, K., Inoue, T., Li, X. B., Maki, Y., Muraki, I. et al. (2002). Long-lasting
change in 5-HT2A receptor-mediated behavior in rats after a single footshock. European Journal
of Pharmacology, 452, 199-204.
Jenck, F., Broekkamp, C. L., & Van Delft, A. M. (1989). Effects of serotonin receptor
antagonists on PAG stimulation induced aversion: different contributions of 5HT1, 5HT2 and
5HT3 receptors. Psychopharmacology (Berl), 97, 489-495.
Jezova, D., Ochedalski, T., Glickman, M., Kiss, A., & Aguilera, G. (1999). Central
corticotropin-releasing hormone receptors modulate hypothalamic-pituitary-adrenocortical and
sympathoadrenal activity during stress. Neuroscience, 94, 797-802.
Jorgensen, H., Knigge, U., Kjaer, A., Vadsholt, T., & Warberg, J. (1998). Serotonergic
involvement in stress-induced ACTH release. Brain Research, 811, 10-20.
Kalin, N. H. & Takahashi, L. K. (1990). Fear-motivated behavior induced by prior shock
experience is mediated by corticotropin-releasing hormone systems. Brain Research, 509, 80-84.
Kalivas, P. W., Duffy, P., & Eberhardt, H. (1990). Modulation of A10 dopamine neurons
by gamma-aminobutyric acid agonists. Journal of Pharmacology and Experimental Therapies,
253, 858-866.
Kaur, P. & Ahlenius, S. (2000). Non-serotonergic potentiation by (-)-pindolol of DOIinduced forward locomotion in rats: possible involvement of beta-adrenoceptors? Journal of
Neural Transmission, 107, 903-917.

83

Kennett, G. A., Chaouloff, F., Marcou, M., & Curzon, G. (1986). Female rats are more
vulnerable than males in an animal model of depression: the possible role of serotonin. Brain
Research, 382, 416-421.
Kirby, L. G., Chou-Green, J. M., Davis, K., & Lucki, I. (1997). The effects of different
stressors on extracellular 5-hydroxytryptamine and 5-hydroxyindoleacetic acid. Brain Research,
760, 218-230.
Klimiuk, P. S., Kay, E. A., Mitchell, W. S., Taylor, L., Gush, R., Gould, S. et al. (1989).
Ketanserin: an effective treatment regimen for digital ischaemia in systemic sclerosis.
Scandinavian Journal of Rheumatology, 18, 107-111.
Koek, W., Jackson, A., & Colpaert, F. C. (1992). Behavioral pharmacology of antagonists
at 5-HT2/5-HT1C receptors. Neuroscience and Biobehavioral Reviews, 16, 95-105.
Koks, S., Beljajev, S., Koovit, I., Abramov, U., Bourin, M., & Vasar, E. (2001). 8-OHDPAT, but not deramciclane, antagonizes the anxiogenic-like action of paroxetine in an elevated
plus-maze. Psychopharmacology (Berl), 153, 365-372.
Koob, G. F. (1999). Corticotropin-releasing factor, norepinephrine, and stress. Biological
Psychiatry, 46, 1167-1180.
Koob, G. F., Heinrichs, S. C., Pich, E. M., Menzaghi, F., Baldwin, H., Miczek, K. et al.
(1993). The role of corticotropin-releasing factor in behavioural responses to stress. CIBA
Foundation Symposium, 172, 277-289.
Krebs-Thomson, K. & Geyer, M. A. (1996). The role of 5-HT(1A) receptors in the
locomotor-suppressant effects of LSD: WAY-100635 studies of 8-OH-DPAT, DOI and LSD in
rats. Behavioral Pharmacology, 7, 551-559.
Kshama, D., Hrishikeshavan, H. J., Shanbhogue, R., & Munonyedi, U. S. (1990).
Modulation of baseline behavior in rats by putative serotonergic agents in three ethoexperimental
paradigms. Behavioral and Neural Biology, 54, 234-253.
Kursar, J. D., Nelson, D. L., Wainscott, D. B., & Baez, M. (1994). Molecular cloning,
functional expression, and mRNA tissue distribution of the human 5-hydroxytryptamine2B
receptor. Molecular Pharmacology, 46, 227-234.
Labrecque, J., Fargin, A., Bouvier, M., Chidiac, P., & Dennis, M. (1995). Serotonergic
antagonists differentially inhibit spontaneous activity and decrease ligand binding capacity of the
rat 5-hydroxytryptamine type 2C receptor in Sf9 cells. Molecular Pharmacology, 48, 150-159.
Larson, A. A. & Kondzielski, M. H. (1982). Serotonin-induced gnawing in rats:
comparison with tail pinch-induced gnawing. Pharmacology Biochemistry and Behavior, 16, 407409.

84

Laue, L., Loriaux, D. L., & Chrousos, G. P. (1988). Glucocorticoid antagonists and the
role of glucocorticoids at the resting and stress state. Advances in Experimental Medicine and
Biology, 245, 225-235.
Lee, K., Dixon, A. K., & Pinnock, R. D. (1999). Serotonin depolarizes hippocampal
interneurones in the rat stratum oriens by interaction with 5HT2 receptors. Neuroscience Letters,
270, 56-58.
Lee, M. D., Kennett, G. A., Dourish, C. T., & Clifton, P. G. (2002). 5-HT1B receptors
modulate components of satiety in the rat: behavioural and pharmacological analyses of the
selective serotonin1B agonist CP-94,253. Psychopharmacology (Berl), 164, 49-60.
Levine, A. S. & Morley, J. E. (1981). Stress-induced eating in rats. American Journal of
Physiology, 241, R72-R76.
Levine, R. & Levine, S. (1989). Role of the pituitary-adrenal hormones in the acquisition
of schedule-induced polydipsia. Behavioral Neuroscience, 103, 621-637.
Lin, D. & Parsons, L. H. (2002). Anxiogenic-like effect of serotonin(1B) receptor
stimulation in the rat elevated plus-maze. Pharmacology Biochemistry and Behavior, 71, 581587.
Lingjaerde, O. (1969). Uptake of serotonin in blood platelets: Dependence on sodium and
chloride, and inhibition by choline. FEBS Letters, 3, 103-106.
Liu, R., Jolas, T., & Aghajanian, G. (2000). Serotonin 5-HT(2) receptors activate local
GABA inhibitory inputs to serotonergic neurons of the dorsal raphe nucleus. Brain Research,
873, 34-45.
Lopez, J. F., Akil, H., & Watson, S. J. (1999). Neural circuits mediating stress. Biological
Psychiatry, 46, 1461-1471.
Luine, V. (2002). Sex differences in chronic stress effects on memory in rats. Stress., 5,
205-216.
Martin, G. R. (1994). Vascular receptors for 5-hydroxytryptamine: distribution, function
and classification. Pharmacology and Therapeutics, 62, 283-324.
McCall, R. B. & Clement, M. E. (1994). Role of serotonin1A and serotonin2 receptors in
the central regulation of the cardiovascular system. Pharmacology Reviews, 46, 231-243.
Melo, L. L. & Brandao, M. L. (1995). Role of 5-HT1A and 5-HT2 receptors in the
aversion induced by electrical stimulation of inferior colliculus. Pharmacology Biochemistry and
Behavior, 51, 317-321.

85

Mendlin, A., Martin, F. J., & Jacobs, B. L. (1999). Dopaminergic input is required for
increases in serotonin output produced by behavioral activation: an in vivo microdialysis study in
rat forebrain. Neuroscience, 93, 897-905.
Merriam-Webster (1987). Webster's Ninth New Collegiate Dictionary. Springfield,
Massachusetts: Merriam-Webster, Inc.
Mikuni, M., Kagaya, A., Takahashi, K., & Meltzer, H. Y. (1992). Serotonin but not
norepinephrine-induced calcium mobilization of platelets is enhanced in affective disorders.
Psychopharmacology (Berl), 106, 311-314.
Millan, M. J. (2003). The neurobiology and control of anxious states. Progress in
Neurobiology, 70, 83-244.
Minami, M., Endo, T., Hirafuji, M., Hamaue, N., Liu, Y., Hiroshige, T. et al. (2003).
Pharmacological aspects of anticancer drug-induced emesis with emphasis on serotonin release
and vagal nerve activity. Pharmacology and Therapeutics, 99, 149-165.
Mora, P. O., Netto, C. F., & Graeff, F. G. (1997). Role of 5-HT2A and 5-HT2C receptor
subtypes in the two types of fear generated by the elevated T-maze. Pharmacology Biochemistry
and Behavior, 58, 1051-1057.
Morley, J. E., Levine, A. S., Murray, S. S., Kneip, J., & Grace, M. (1982). Peptidergic
regulation of stress-induced eating. American Journal of Physiology, 243, R159-R163.
Moser, P. C. & Sanger, D. J. (1999). 5-HT1A receptor antagonists neither potentiate nor
inhibit the effects of fluoxetine and befloxatone in the forced swim test in rats. European Journal
of Pharmacology, 372, 127-134.
Nagayama, H. & Lu, J. Q. (1996). Circadian rhythm in the responsiveness of central 5HT2A receptor to DOI in rats. Psychopharmacology (Berl), 127, 113-116.
Nakamura, K. & Kurasawa, M. (2001). Anxiolytic effects of aniracetam in three different
mouse models of anxiety and the underlying mechanism. European Journal of Pharmacology,
420, 33-43.
Nankai, M., Yamada, S., Muneoka, K., & Toru, M. (1995). Increased 5-HT2 receptormediated behavior 11 days after shock in learned helplessness rats. European Journal of
Pharmacology, 281, 123-130.
Nebigil, C. G., Etienne, N., Schaerlinger, B., Hickel, P., Launay, J. M., & Maroteaux, L.
(2001). Developmentally regulated serotonin 5-HT2B receptors. International Journal of
Developmental Neuroscience, 19, 365-372.

86

Nemeroff, C. B. (1988). The role of corticotropin-releasing factor in the pathogenesis of
major depression. Pharmacopsychiatry, 21, 76-82.
Nemeroff, C. B. (1992). New vistas in neuropeptide research in neuropsychiatry: focus on
corticotropin-releasing factor. Neuropsychopharmacology, 6, 69-75.
Nic Dhonnchadha, B. A., Bourin, M., & Hascoet, M. (2003). Anxiolytic-like effects of 5HT2 ligands on three mouse models of anxiety. Behavioral Brain Research, 140, 203-214.
Nic Dhonnchadha, B. A., Hascoet, M., Jolliet, P., & Bourin, M. (2003). Evidence for a 5HT2A receptor mode of action in the anxiolytic-like properties of DOI in mice. Behavioral Brain
Research, 147, 175-184.
Nicholson, R., Small, J., Dixon, A. K., Spanswick, D., & Lee, K. (2003). Serotonin
receptor mRNA expression in rat dorsal root ganglion neurons. Neuroscience Letrers, 337, 119122.
Njung'e, K. & Handley, S. L. (1991). Effects of 5-HT uptake inhibitors, agonists and
antagonists on the burying of harmless objects by mice; a putative test for anxiolytic agents.
British Journal of Pharmacology, 104, 105-112.
Nogueira, R. L. & Graeff, F. G. (1995). Role of 5-HT receptor subtypes in the modulation
of dorsal periaqueductal gray generated aversion. Pharmacology Biochemistry and Behavior, 52,
1-6.
Nonaka, K. O. (1999). Involvement of 5-HT3 receptors in the prolactin release induced by
immobilization stress in rats. Progress in Neuropsychopharmacology & Biological Psychiatry,
23, 497-503.
Olivier, B., Molewijk, E., van Oorschot, R., van der, P. G., Zethof, T., van der, H. J. et al.
(1994). New animal models of anxiety. European Neuropsychopharmacology, 4, 93-102.
Olivier, B., Molewijk, H. E., Van der Heyden, J. A., van Oorschot, R., Ronken, E., Mos,
J. et al. (1998). Ultrasonic vocalizations in rat pups: effects of serotonergic ligands. Neuroscience
& Biobehavioral Reviews, 23, 215-227.
Onaivi, E. S., Bishop-Robinson, C., Darmani, N. A., & Sanders-Bush, E. (1995).
Behavioral effects of (+/-)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane, (DOI) in the
elevated plus-maze test. Life Sciences, 57, 2455-2466.
Otero Losada, M. E. (1989). Acute stress and GABAergic function in the rat brain.
British Journal of Pharmacology, 96, 507-512.
Owens, M. J. & Nemeroff, C. B. (1991). Physiology and pharmacology of corticotropinreleasing factor. Pharmacology Reviews, 43, 425-473.

87

Patkar, A. A., Gottheil, E., Berrettini, W. H., Hill, K. P., Thornton, C. C., & Weinstein, S.
P. (2003). Relationship between Platelet Serotonin Uptake Sites and Measures of Impulsivity,
Aggression, and Craving among African-American Cocaine Abusers. American Journal of
Addiction, 12, 432-447.
Pazos, A., Cortes, R., & Palacios, J. M. (1985). Quantitative autoradiographic mapping of
serotonin receptors in the rat brain. II. Serotonin-2 receptors. Brain Research, 346, 231-249.
Pazos, A., Probst, A., & Palacios, J. M. (1987). Serotonin receptors in the human brain-IV. Autoradiographic mapping of serotonin-2 receptors. Neuroscience, 21, 123-139.
Pehek, E. A., McFarlane, H. G., Maguschak, K., Price, B., & Pluto, C. P. (2001).
M100,907, a selective 5-HT(2A) antagonist, attenuates dopamine release in the rat medial
prefrontal cortex. Brain Research, 888, 51-59.
Pei, Q., Zetterstrom, T., & Fillenz, M. (1990). Tail pinch-induced changes in the turnover
and release of dopamine and 5-hydroxytryptamine in different brain regions of the rat.
Neuroscience, 35, 133-138.
Peng, W. H., Wu, C. R., Chen, C. S., Chen, C. F., Leu, Z. C., & Hsieh, M. T. (2004).
Anxiolytic effect of berberine on exploratory activity of the mouse in two experimental anxiety
models: interaction with drugs acting at 5-HT receptors. Life Sciences, 75, 2451-2462.
Pericic, D. (2003). Swim stress inhibits 5-HT2A receptor-mediated head twitch behaviour
in mice. Psychopharmacology (Berl), 167, 373-379.
Raghavendra, V. & Kulkarni, S. K. (2000b). Melatonin reversal of DOI-induced
hypophagia in rats; possible mechanism by suppressing 5-HT(2A) receptor-mediated activation of
HPA axis. Brain Research, 860, 112-118.
Raghavendra, V. & Kulkarni, S. K. (2000a). Melatonin reversal of DOI-induced
hypophagia in rats; possible mechanism by suppressing 5-HT(2A) receptor-mediated activation of
HPA axis. Brain Research, 860, 112-118.
Redrobe, J. P. & Bourin, M. (1997). Effects of pretreatment with clonidine, lithium and
quinine on the activities of antidepressant drugs in the mouse tail suspension test. Fundamental
and Clinical Pharmacology, 11, 381-386.
Rodriguez Echandia, E. L., Broitman, S. T., & Foscolo, M. R. (1983). Effect of
serotonergic and catecholaminergic antagonists on mild-stress-induced excessive grooming in the
rat. Behavioral Neuroscience, 97, 1022-1024.
Rowland, N. E. & Souquet, A. M. (1989). [Serotonin, food intake and body weight].
Annales de Medecine Interne (Paris), 140 Suppl 1, 8-11.

88

Rueter, L. E., Fornal, C. A., & Jacobs, B. L. (1997). A critical review of 5-HT brain
microdialysis and behavior. Reviews in Neuroscience, 8, 117-137.
Rueter, L. E. & Jacobs, B. L. (1996). A microdialysis examination of serotonin release in
the rat forebrain induced by behavioral/environmental manipulations. Brain Research, 739, 57-69.
Sakaue, M., Ago, Y., Sowa, C., Koyama, Y., Baba, A., & Matsuda, T. (2003). The 5HT1A receptor agonist MKC-242 increases the exploratory activity of mice in the elevated plusmaze. European Journal of Pharmacology, 458, 141-144.
Sanchez, C. (1993). Effect of serotonergic drugs on footshock-induced ultrasonic
vocalization in adult male rats. Behavioral Pharmacology, 4, 269-277.
Sanchez, C. & Mork, A. (1999). N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline studies
on the role of 5-HT1A and 5-HT2 receptors in mediating foot-shock-induced ultrasonic
vocalisation in adult rats. European Neuropsychopharmacology, 9, 287-294.
Saphier, D., Farrar, G. E., & Welch, J. E. (1995). Differential inhibition of stress-induced
adrenocortical responses by 5-HT1A agonists and by 5-HT2 and 5-HT3 antagonists.
Psychoneuroendocrinology, 20, 239-257.
Saxena, P. R. (1995). Serotonin receptors: subtypes, functional responses and therapeutic
relevance. Pharmacology and Therapeutics, 66, 339-368.
Saxena, P. R. & Villalon, C. M. (1990). Cardiovascular effects of serotonin agonists and
antagonists. Journal of Cardiovascualr Pharmacology, 15 Suppl 7, S17-S34.
Scalzitti, J. M., Cervera, L. S., Smith, C., & Hensler, J. G. (1999). Serotonin2A receptor
modulation of D1 dopamine receptor-mediated grooming behavior. Pharmacology Biochemistry
and Behavior, 63, 279-284.
Schreiber, R. & De Vry, J. (2002). Role of 5-hT2C receptors in the hypophagic effect of
m-CPP, ORG 37684 and CP-94,253 in the rat. Progress in Neuropsychopharmacology and
Biological Psychiatry, 26, 441-449.
Schreiber, R., Melon, C., & De Vry, J. (1998). The role of 5-HT receptor subtypes in the
anxiolytic effects of selective serotonin reuptake inhibitors in the rat ultrasonic vocalization test.
Psychopharmacology (Berl), 135, 383-391.
Schutz, M. T., de Aguiar, J. C., & Graeff, F. G. (1985). Anti-aversive role of serotonin in
the dorsal periaqueductal grey matter. Psychopharmacology (Berl), 85, 340-345.
Serres, F., Azorin, J. M., Valli, M., & Jeanningros, R. (1999). Evidence for an increase in
functional platelet 5-HT2A receptors in depressed patients using the new ligand [125I]-DOI.
European Psychiatry, 14, 451-457.

89

Setem, J., Pinheiro, A. P., Motta, V. A., Morato, S., & Cruz, A. P. (1999).
Ethopharmacological analysis of 5-HT ligands on the rat elevated plus-maze. Pharmacology
Biochemistry and Behavior, 62, 515-521.
Silva, M., Hetem, L. A., Guimaraes, F. S., & Graeff, F. G. (2001). Opposite effects of
nefazodone in two human models of anxiety. Psychopharmacology (Berl), 156, 454-460.
Simansky, K. J. (1996). Serotonergic control of the organization of feeding and satiety.
Behavioral Brain Research, 73, 37-42.
Singewald, N., Kaehler, S., Hemeida, R., & Philippu, A. (1997). Release of serotonin in
the rat locus coeruleus: effects of cardiovascular, stressful and noxious stimuli. European Journal
of Neuroscience, 9, 556-562.
Sinner, C., Kaehler, S. T., Philippu, A., & Singewald, N. (2001). Role of nitric oxide in
the stress-induced release of serotonin in the locus coeruleus. Naunyn Schmiedebergs Archives of
Pharmacology, 364, 105-109.
Steckler, T., Ruggeberg-Schmidt, K., & Muller-Oerlinghausen, B. (1993). Human platelet
5-HT2 receptor binding sites re-evaluated: a criticism of current techniques [corrected]. Journal
of Neural Transmission, Genetics Section, 92, 11-24.
Swiergiel, A. H., Takahashi, L. K., Rubin, W. W., & Kalin, N. H. (1992). Antagonism of
corticotropin-releasing factor receptors in the locus coeruleus attenuates shock-induced freezing
in rats. Brain Research, 587, 263-268.
Tabachnick, B. G. & Fidell, L. S. (2001). Limitations to Multivariate Analysis of Variance
and Covariance. In R.Pascal (Ed.), Using Multivariate Statistics (4th ed., pp. 328). Boston: Allyn
and Bacon.
Tadano, T., Hozumi, M., Satoh, N., Oka, R., Hishinuma, T., Mizugaki, M. et al. (2001).
Central serotonergic mechanisms on head twitch response induced by benzodiazepine receptor
agonists. Pharmacology, 62, 157-162.
Takao, K., Nagatani, T., Kitamura, Y., Kawasaki, K., Hayakawa, H., & Yamawaki, S.
(1995). Chronic forced swim stress of rats increases frontal cortical 5-HT2 receptors and the wetdog shakes they mediate, but not frontal cortical beta-adrenoceptors. European Journal of
Pharmacology, 294, 721-726.
Truitt, W., Harrison, L., Guptarak, J., White, S., Hiegel, C., & Uphouse, L. (2003).
Progesterone attenuates the effect of the 5-HT1A receptor agonist, 8-OH-DPAT, and of mild
restraint on lordosis behavior. Brain Research, 974, 202-211.

90

Uphouse, L., White, S., Harrison, L., Hiegel, C., Majumdar, D., Guptarak, J. et al. (2003).
Restraint accentuates the effects of 5-HT2 receptor antagonists and a 5-HT1A receptor agonist
on lordosis behavior. Pharmacology Biochemistry and Behavior, 76, 63-73.
Vahabzadeh, A. & Fillenz, M. (1994). Comparison of stress-induced changes in
noradrenergic and serotonergic neurons in the rat hippocampus using microdialysis. European
Journal of Neuroscience, 6, 1205-1212.
Van Oekelen, D., Megens, A., Meert, T., Luyten, W. H., & Leysen, J. E. (2003).
Functional study of rat 5-HT2A receptors using antisense oligonucleotides. Journal of
Neurochemistry, 85, 1087-1100.
Vickers, S. P. & Dourish, C. T. (2004). Serotonin receptor ligands and the treatment of
obesity. Current Opinion in Investigational Drugs, 5, 377-388.
Villalon, C. M., Terron, J. A., Ramirez-San Juan, E., & Saxena, P. R. (1995). 5hydroxytryptamine: considerations about discovery, receptor classification and relevance to
medical research. Archives of Medical Research, 26, 331-344.
Watling, K. J. (2001). The Sigma-RBI Handbook of Receptor Classifcation and Signal
Transduction. (4th ed.) Natick, MA: Sigma-RBI.
Welch, J. E. & Saphier, D. (1994). Central and peripheral mechanisms in the stimulation
of adrenocortical secretion by the 5-hydroxytryptamine2 agonist, (+-)-1-(2,5-dimethoxy-4iodophenyl)-2-aminopropane. Journal of Pharmacology and Experimental Therapies, 270, 918928.
Whitton, P. S., Sarna, G. S., Datla, K. P., & Curzon, G. (1991). Effects of tianeptine on
stress-induced behavioural deficits and 5-HT dependent behaviour. Psychopharmacology (Berl),
104, 81-85.
Winslow, J. T. & Insel, T. R. (1991). Serotonergic modulation of the rat pup ultrasonic
isolation call: studies with 5HT1 and 5HT2 subtype-selective agonists and antagonists.
Psychopharmacology (Berl), 105, 513-520.
Yamada, S., Nankai, M., & Toru, M. (1993). Acute immobilization stress reduces (+/-)
DOI induced 5-HT2-mediated head shakes in rats. Japanese Journal of Psychiatry and
Neurology, 47, 414-415.
Yamada, S., Watanabe, A., Nankai, M., & Toru, M. (1995). Acute immobilization stress
reduces (+/-)DOI-induced 5-HT2A receptor-mediated head shakes in rats. Psychopharmacology
(Berl), 119, 9-14.

91

Yan, Q., Reith, M. E., & Yan, S. (2000). Enhanced accumbal dopamine release following
5-HT(2A) receptor stimulation in rats pretreated with intermittent cocaine. Brain Research, 863,
254-258.
Zangrossi, H., Jr., Viana, M. B., Zanoveli, J., Bueno, C., Nogueira, R. L., & Graeff, F. G.
(2001). Serotonergic regulation of inhibitory avoidance and one-way escape in the rat elevated Tmaze. Neuroscience & Biobehavioral Reviews, 25, 637-645.
Zangrossi, J. H. & Graeff, F. G. (1994). Behavioral effects of intra-amygdala injections of
GABA and 5-HT acting drugs in the elevated plus-maze. Brazilian Journal of Medical and
Biological Research, 27, 2453-2456.
Zanoveli, J. M., Nogueira, R. L., & Zangrossi, H., Jr. (2003). Serotonin in the dorsal
periaqueductal gray modulates inhibitory avoidance and one-way escape behaviors in the elevated
T-maze. European Journal of Pharmacology, 473, 153-161.

92

APPENDIX: NON-SIGNIFICANT RESULTS
Table 4: Non-significant findings from Experiments 1 & 4: Peripheral Injection.
Dependent
Variable

Grooming

Boli in tail pinch

Group

Saline
DOI
0.1 mg/kg
DOI
0.5 mg/kg
DOI
1.0 mg/kg
KET
0.5 mg/kg
KET
2.5 mg/kg
KET
5.0 mg/kg
Saline
DOI
0.1 mg/kg
DOI
0.5 mg/kg
DOI
1.0 mg/kg
KET
0.5 mg/kg
KET
2.5 mg/kg
KET
5.0 mg/kg

Mean
(S.E.)
23.80 (5.93)
13.61 (7.66)

Degrees of
Freedom

F

Probability
Value (p)

6, 72

1.831

.105

6, 72

1.400

.226

8.05 (4.69)
9.02 (6.63)
20.42 (6.93)
14.67 (7.26)
31.01 (7.26)
1.07 (.28)
.89 (.36)
.54 (.22)
.000 (.31)
.82 (.32)
.70 (.34)
.20 (.34)
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Dependent
Variable

Eating

Line crosses

Rotarod

Group

Saline
DOI
0.1 mg/kg
DOI
0.5 mg/kg
DOI
1.0 mg/kg
KET
0.5 mg/kg
KET
2.5 mg/kg
KET
5.0 mg/kg
Saline
DOI
0.1 mg/kg
DOI
0.5 mg/kg
DOI
1.0 mg/kg
KET
0.5 mg/kg
KET
2.5 mg/kg
KET
5.0 mg/kg
Saline
DOI
0.1 mg/kg
DOI
0.5 mg/kg
DOI
1.0 mg/kg
KET
0.5 mg/kg
KET
2.5 mg/kg
KET
5.0 mg/kg

Mean
(S.E.)
.31 (.22)
.14 (.29)

Degrees of
Freedom

F

Probability
Value (p)

6, 72

1.213

.309

6, 72

1.448

.209

6, 69

.586

.74

.12 (.17)
.02 (.25)
.80 (.26)
.51 (.27)
.71 (.27)
16.00 (1.77)
14.22 (2.28)
18.75 (1.40)
15.58 (1.98)
15.18 (2.06)
16.20 (2.17)
11.80 (2.17)
26.64 (1.88)
28.06 (2.34)
28.06 (2.12)
27.70 (2.12)
23.78 (2.12)
27.31 (2.22)
25.01 (2.22)
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Table 5: Non-significant findings from Experiment 2: Central Injection.
Dependent
Variable

Oral stereotopy
with food
Oral stereotopy
without food

Grooming

Boli in tail pinch

Eating

Gnawing

Linecrosses

Rears

Freezing

Rotarod

Group

Mean (S.E.)

Saline
DOI 20µg
DOI 100µg
DOI 200µg
Saline
DOI 20µg
DOI 100µg
DOI 200µg
Saline
DOI 20µg
DOI 100µg
DOI 200µg
Saline
DOI 20µg
DOI 100µg
DOI 200µg
Saline
DOI 20µg
DOI 100µg
DOI 200µg
Saline
DOI 20µg
DOI 100µg
DOI 200µg
Saline
DOI 20µg
DOI 100µg
DOI 200µg
Saline
DOI 20µg
DOI 100µg
DOI 200µg
Saline
DOI 20µg
DOI 100µg
DOI 200µg
Saline
DOI 20µg
DOI 100µg
DOI 200µg

53.77 (17.88)
43.96 (15.28)
37.43 (17.47)
38.63 (13.93)
49.77 (11.46)
54.31 (14.95)
35.10 (10.26)
25.91 (7.15)
3.28 (1.67)
7.34 (2.34)
3.41 (1.63)
1.94 (1.14)
.86 (.49)
1.54 (.50)
1.29 (.44)
1.64 (.45)
.12 (.04)
.10 (.03)
.10 (.05)
.10 (.03)
5.14 (2.12)
2.04 (.93)
1.72 (1.03)
2.56 (.88)
7.71 (1.88)
12.62 (2.64)
8.57 (2.07)
12.64 (2.13)
3.07 (.79)
4.31 (.99)
1.86 (.60)
3.36 (1.51)
35.09 (9.54)
18.97 (10.39)
57.51 (7.61)
19.90 (19.12)
26.04 (2.20)
26.85 (2.20)
27.02 (2.43)
22.70 (2.10)
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Degrees of
Freedom

F

Probability
Value (p)

3, 50

.227

.877

3, 50

.829

.484

3, 50

1.779

.163

3, 50

.641

.592

3, 50

.111

.953

3, 50

1.32

.278

3, 50

1.821

.155

3, 50

.964

.417

3, 50

2.161

.104

3, 39

.868

.466

Table 6: Non-significant findings from Experiment 3: Central + Peripheral Injection.
Dependent
Variable

Oral stereotopy
without food

Grooming

Vocals

Boli in tail pinch

Line crosses

Rears

Freezing

Flat body
posture

Rotarod

Group

Mean
(S.E.)

Degrees of
Freedom

F

Probability
Value (p)

Saline
DOI
200µg+0.1
mg/kg
Saline
DOI
200µg+0.1
mg/kg
Saline
DOI
200µg+0.1
mg/kg
Saline

28.69 (8.15)
25.61 (8.38)

1, 21

.014

.908

10.98 (4.99)
6.79 (3.19)

1, 21

.479

.496

5.67 (3.02)
7.36 (2.89)

1, 21

.163

.690

DOI
200µg+0.1
mg/kg
Saline
DOI
200µg+0.1
mg/kg
Saline
DOI
200µg+0.1
mg/kg
Saline
DOI
200µg+0.1
mg/kg
Saline

1.36 (.31)

1, 21

3.047

.095

13.92 (2.11)
14.09 (2.72)

1, 21

.003

.960

4.33 (1.26)
3.64 (1.40)

1, 21

.138

.714

32.80 (16.72)
19.81 (12.90)

1, 21

.368

.550

1

χ2 = .004

.949

4, 65

1.20

.318

DOI
200µg+0.1
mg/kg
Saline
DOI
200µg+0.1
mg/kg

.67 (.26)

11 absent
1 present
10 absent
1 present
26.80 (2.91)
19.84 (2.74)

.
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Table 7: Non-significant findings from Experiment 5: Double Peripheral Injection.
Dependent
Variable

Oral stereotopy
without food

Grooming

Boli in tail pinch

Group

Mean
(S.E.)

Double Saline
DOI 0.5
mg/kg +
Saline
DOI 1.0
mg/kg +
Saline
KET 5.0
mg/kg +
Saline
DOI 0.5
mg/kg + KET
5.0 mg/kg
DOI 1.0
mg/kg + KET
5.0 mg/kg
Double Saline
DOI 0.5
mg/kg +
Saline
DOI 1.0
mg/kg +
Saline
KET 5.0
mg/kg +
Saline
DOI 0.5
mg/kg + KET
5.0 mg/kg
DOI 1.0
mg/kg + KET
5.0 mg/kg
Double Saline
DOI 0.5
mg/kg +
Saline
DOI 1.0
mg/kg +
Saline
KET 5.0
mg/kg +
Saline
DOI 0.5
mg/kg + KET
5.0 mg/kg
DOI 1.0
mg/kg + KET
5.0 mg/kg

40.55 (9.71)
42.93 (9.71)

Degrees of
Freedom

F

Probability
Value (p)

5, 90

1.616

.164

5, 90

2.213

.060

5, 90

1.839

.113

21.62 (9.71)
11.15 (9.71)
28.07 (9.71)
20.38 (9.71)
15.43 (5.82)
3.45 (5.82)
4.69 (5.82)
21.17 (5.82)
6.34 (5.82)
22.97 (5.82)
.56 (.27)
1.13 (.27)
.44 (.27)
.50 (.27)
.94 (.27)
1.31 (.27)

97

Dependent
Variable

Gnawing

Line crosses

Bodyshakes

Group

Mean
(S.E.)

Double Saline
DOI 0.5
mg/kg +
Saline
DOI 1.0
mg/kg +
Saline
KET 5.0
mg/kg +
Saline
DOI 0.5
mg/kg + KET
5.0 mg/kg
DOI 1.0
mg/kg + KET
5.0 mg/kg
Double Saline
DOI 0.5
mg/kg +
Saline
DOI 1.0
mg/kg +
Saline
KET 5.0
mg/kg +
Saline
DOI 0.5
mg/kg + KET
5.0 mg/kg
DOI 1.0
mg/kg + KET
5.0 mg/kg
Double Saline
DOI 0.5
mg/kg +
Saline
DOI 1.0
mg/kg +
Saline
KET 5.0
mg/kg +
Saline
DOI 0.5
mg/kg + KET
5.0 mg/kg
DOI 1.0
mg/kg + KET
5.0 mg/kg

1.31 (.63)
.69 (.63)

Degrees of
Freedom

F

Probability
Value (p)

5, 90

1.614

.164

5, 90

.734

.593

5, 90

1.481

.204

.20 (.63)
2.08 (.63)
2.27 (.63)
1.12 (.63)
13.56 (1.45)
14.63 (1.45)
15.00 (1.45)
14.63 (1.45)
11.81 (1.45)
12.81 (1.45)
.06 (.08)
.25 (.08)
.19 (.08)
5.55E-17 (.08)
.00 (.08)
.13 (.08)
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Dependent
Variable

Freezing

Rotarod

Group

Mean
(S.E.)

Double Saline
DOI 0.5
mg/kg +
Saline
DOI 1.0
mg/kg +
Saline
KET 5.0
mg/kg +
Saline
DOI 0.5
mg/kg + KET
5.0 mg/kg
DOI 1.0
mg/kg + KET
5.0 mg/kg
Double Saline
DOI 0.5
mg/kg +
Saline
DOI 1.0
mg/kg +
Saline
KET 5.0
mg/kg +
Saline
DOI 0.5
mg/kg + KET
5.0 mg/kg
DOI 1.0
mg/kg + KET
5.0 mg/kg

1.76 (5.70)
21.37 (5.70)

Degrees of
Freedom

F

Probability
Value (p)

5, 90

1.897

.103

4, 65

1.203

.318

12.69 (5.70)
8.40 (5.70)
14.75 (5.70)
1.12 (5.70)
28.41 (1.42)
*Group not
included in
analysis
25.36 (1.42)
29.34 (1.64)
28.77 (1.64)
26.68 (1.52)

*The rotarod data for the group that was administered the low dose of DOI + Saline was not
available for analysis (due to a data collection/recording error), however, it is not anticipated that
these data would have shown any difference from the control group as neither the high dose of
DOI + Saline nor the 0.5 dose of DOI alone (from Experiment 1) resulted in motor impairment.
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